<SEC-DOCUMENT>0001213900-24-101629.txt : 20241122
<SEC-HEADER>0001213900-24-101629.hdr.sgml : 20241122
<ACCEPTANCE-DATETIME>20241122163046
ACCESSION NUMBER:		0001213900-24-101629
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20241122
DATE AS OF CHANGE:		20241122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283338
		FILM NUMBER:		241490236

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea0222133-424b3_neuro.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>




<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed pursuant to Rule 424(b)(3)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration No. 333-283338</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Up to 10,000,000 Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroSense Therapeutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus relates to the offer and sale
of up to 10,000,000 of our ordinary shares, no par value per share, by YA II PN, LTD., or YA or the Selling Shareholder, a Cayman Islands
exempt limited partnership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The ordinary shares represented by ordinary shares being offered by
the Selling Shareholder are to be issued pursuant to the Standby Equity Purchase Agreement dated October 31, 2024 that we entered into
with YA, or the Purchase Agreement. We are not selling any securities under this prospectus and will not receive any of the proceeds from
the sale of our ordinary shares by the Selling Shareholder. However, we may receive up to $30.0 million in aggregate gross proceeds from
sales of our ordinary shares, or the Advance Shares, to YA that we may make under the Purchase Agreement, from time to time, each such occurrence, an Advance, during the
36 months following the execution of the Purchase Agreement. Pursuant to the Purchase Agreement, we issued an aggerate of 224,697 ordinary
shares, or the Commitment Shares, to YA as consideration for its irrevocable commitment to purchase our ordinary shares under the Purchase
Agreement. The additional 9,775,303 ordinary shares represent Advance Shares that may be offered pursuant to this prospectus and purchased
by YA from time to time pursuant to the Purchase Agreement at a price equal to 97% of the lowest of the three daily volume weighted average
prices, or VWAPs, during a pricing period as set forth in the Purchase Agreement and would be subject to certain limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Shareholder may sell the ordinary
shares included in this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling
Shareholder may sell the shares in the section entitled &#8220;Plan of Distribution.&#8221; The Selling Shareholder is an &#8220;underwriter&#8221;
within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Shareholder will pay all brokerage
fees and commissions and similar expenses in connection with the offer and sale of the shares by the Selling Shareholder pursuant to this
prospectus. We will pay the expenses (except brokerage fees and commissions and similar expenses) incurred in registering under the Securities
Act the offer and sale of the shares included in this prospectus by the Selling Shareholder. See &#8220;Plan of Distribution.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ordinary shares and publicly-listed warrants, each warrant exercisable
for one ordinary share, are traded on the Nasdaq Capital Market, or Nasdaq, under the symbols &ldquo;NRSN&rdquo; and &ldquo;NRSNW,&rdquo;
respectively. The last reported sale price for our ordinary shares on November 18, 2024 as quoted on Nasdaq was $1.18 per share, and the
last reported sale price for our warrants on November 18, 2024 as quoted on Nasdaq was $0.12 per warrant.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an &#8220;emerging
growth company&#8221; and a &#8220;foreign private issuer&#8221; as defined under the U.S. federal securities laws, and as such, will
be eligible for reduced public company disclosure requirements. See &#8220;About the Company&#8212;Implications of Being an Emerging Growth
Company&#8221; and &#8220;About the Company&#8212;Implications of Being a Foreign Private Issuer&#8221; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Investing in our securities involves a high
degree of risk. See &#8220;Risk Factors&#8221; beginning on page 9.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Neither the Securities and Exchange Commission
(or the SEC), nor any state or other foreign securities commission has approved nor disapproved these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is November 22, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; width: 90%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">About this Prospectus</FONT></A></TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">ii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Trademarks, Service Marks and Tradenames</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">ii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Market and Industry Data</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">ii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Cautionary Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: center">iii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">The Offering</FONT></A></TD>
    <TD STYLE="text-align: center">8</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Selling Shareholder</FONT></A></TD>
    <TD STYLE="text-align: center">16</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Plan of Distribution</FONT></A></TD>
    <TD STYLE="text-align: center">17</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Description of Share Capital</FONT></A></TD>
    <TD STYLE="text-align: center">18</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Expenses</FONT></A></TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">Incorporation by Reference</FONT></A></TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">Enforcement of Civil Liabilities</FONT></A></TD>
    <TD STYLE="text-align: center">28</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus is part of
the registration statement on Form&nbsp;F-1&nbsp;that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) for
the offering of the ordinary shares by the selling shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should not assume that
the information contained in, or incorporated by reference into, this prospectus is accurate on any date subsequent to the date set forth
on the front cover of this prospectus, even though this prospectus is delivered or the ordinary shares covered by this prospectus are
sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in, or incorporated
by reference into, this prospectus in making your investment decision. You should also read and consider the information in the documents
to which we have referred you under the caption &#8220;Where You Can Find Additional Information&#8221; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neither we nor the selling
shareholder has authorized anyone to provide any information or to make any representation other than those contained in, or incorporated
by reference into, this prospectus. You must not rely upon any information or representation not contained in, or incorporated by reference
into, this prospectus. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities
other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy
any securities of the Company in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus, including
the information incorporated by reference herein, contains forward-looking&nbsp;statements that are subject to a number of risks and uncertainties,
many of which are beyond our control. See &#8220;Risk Factors&#8221; and &#8220;Cautionary Note&nbsp;Regarding Forward-Looking&nbsp;Statements.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>TRADEMARKS, SERVICE MARKS AND TRADENAMES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The NeuroSense Therapeutics logo and other trademarks
and service marks of NeuroSense Therapeutics Ltd. appearing in this prospectus or the information incorporated by reference herein are
the property of the Company. Solely for convenience, some of the trademarks, service marks, logos and trade names referred to in this
prospectus are presented without the&nbsp;<SUP>&reg;</SUP>&nbsp;and&nbsp;<SUP>&#8482;</SUP>&nbsp;symbols, but such references are not
intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks,
service marks and trade names. This prospectus, including the information incorporated by reference herein, contains additional trademarks,
service marks and trade names of others. All trademarks, service marks and trade names appearing in this prospectus or the information
incorporated by reference herein are, to our knowledge, the property of their respective owners. We do not intend our use or display of
other companies&#8217; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>MARKET AND INDUSTRY DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus, including the information incorporated by reference herein, contains industry, market and competitive position data that are
based on industry publications and studies conducted by third parties as well as our own internal estimates and research. These industry
publications and third-party&nbsp;studies generally state that the information that they contain has been obtained from sources believed
to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that each of these publications
and third-party&nbsp;studies is reliable, we have not independently verified the market and industry data obtained from these third-party&nbsp;sources.
Forecasts and other forward-looking&nbsp;information obtained from these sources are subject to the same qualifications and uncertainties
as the other forward-looking&nbsp;statements included in, or incorporated by reference into, this prospectus. While we believe our internal
research is reliable and the definition of our market and industry are appropriate, neither such research nor these definitions have been
verified by any independent source.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>CAUTIONARY NOTE REGARDING&nbsp;FORWARD-LOOKING&nbsp;STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus and
certain information incorporated by reference herein contain forward-looking&nbsp;statements within the meaning of Section&nbsp;27A
of the Securities Act and Section&nbsp;21E of the U.S.&nbsp;Securities Exchange&nbsp;Act&nbsp;of&nbsp;1934, as amended (the
&#8220;Exchange&nbsp;Act&#8221;), and other securities laws. Many of the forward-looking&nbsp;statements contained in, or
incorporated by reference into, this prospectus can be identified by the use of forward-looking&nbsp;words such as
&#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221;
&#8220;target,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future
trends, although not all forward-looking&nbsp;statements contain these identifying words.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Forward-looking&nbsp;statements are based on our
management&#8217;s beliefs and assumptions and on information currently available to our management. Such statements are subject to substantial
risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking&nbsp;statements
due to a variety of factors, including, but not limited to, those identified under the section titled &#8220;Risk Factors&#8221; in this
prospectus or the documents incorporated herein. These risks and uncertainties include factors relating to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the going concern reference in our financial statements and
our need for substantial additional financing to achieve our goals;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our limited operating history and history of incurring significant
losses and negative cash flows since our inception, which we anticipate will continue for the foreseeable future;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our dependence on the success of our lead product candidate,
PrimeC, including our obtaining of regulatory approval to market PrimeC in the United&nbsp;States (&#8220;U.S.&#8221;);</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our limited experience in conducting clinical trials and
reliance on clinical research organizations and others to conduct them;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to advance our preclinical product candidates
into clinical development and through regulatory approval;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the results of our clinical trials, which may fail to adequately
demonstrate the safety and efficacy of our product candidates;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to achieve the broad degree of physician adoption
and use and market acceptance necessary for commercial success;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our reliance on third parties in marketing, producing or
distributing products and research materials for certain raw materials, compounds and components necessary to produce PrimeC for clinical
trials and to support commercial scale production of PrimeC, if approved;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our receipt of regulatory clarity and approvals for our therapeutic
candidates and the timing of other regulatory filings and approvals;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">estimates of our expenses, revenues, capital requirements
and our needs for additional financing;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our efforts to obtain, protect or enforce our patents and
other intellectual property rights related to our product candidates and technologies;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to maintain the listing of our ordinary shares
on Nasdaq;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the impact of the public health, political and security situation
in Israel, the U.S. and other countries in which we may obtain approvals for our products or our business;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the impacts on our ongoing and planned trials and manufacturing
as a result of the war in Israel; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">those factors referred to in our most recent Annual Report
on Form 20-F&nbsp;incorporated by reference herein in &#8220;Item 3. Key Information &#8212; D. Risk Factors,&#8221; &#8220;Item 4. Information
on the Company,&#8221; and &#8220;Item&nbsp;5. Operating and Financial Review and Prospects,&#8221; as well as in our most recent Annual
Report on Form 20 generally, which is incorporated by reference into this prospectus.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preceding list is not intended to be an exhaustive
list of all of our risks and uncertainties. As a result of these factors, we cannot assure you that the forward-looking&nbsp;statements
in this prospectus or the documents incorporated herein or therein will prove to be accurate. Furthermore, if our forward-looking&nbsp;statements
prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking&nbsp;statements,
you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and
plans in any specified time frame, or at all.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, statements that &#8220;we believe&#8221;
and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available
to us as of the date of this prospectus or any document incorporated herein or therein, and while we believe such information forms a
reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all relevant information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise required by law, we do not undertake
any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements
in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You should read this prospectus, the documents incorporated
herein and therein, completely and with the understanding that our actual future results may be materially different from what we expect.
We qualify all of our forward-looking&nbsp;statements by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>This summary highlights
information contained elsewhere in or incorporated by reference into this prospectus that we consider important. This summary does not
contain all of the information you should consider before investing in our securities. Before you decide to invest in our securities,
you should read the entire prospectus carefully, including the &#8220;Risk Factors&#8221; section and the financial statements and related
notes incorporated by reference into this prospectus and the other documents incorporated by reference into this prospectus, which are
described under &#8220;Incorporation by Reference&#8221; before making an investment in our securities.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
are a clinical-stage biotechnology company focused on discovering and developing treatments for people living with neurodegenerative diseases,
including ALS AD and PD. We believe these diseases represent some of the most significant unmet medical needs of our time, with limited
effective therapeutic options available. The burden of these diseases on both patients and society is substantial. For example, the average
annual cost of ALS alone is $180,000 per patient, and its estimated annual burden on the U.S. healthcare system is greater than $1 billion.
Due to the complexity of neurodegenerative diseases, our strategy is utilizing a combined therapeutic approach to target multiple disease-related
pathways.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Our
lead therapeutic candidate, PrimeC, is a novel extended-release oral formulation, fixed-dose combination of two FDA-approved drugs, ciprofloxacin
and celecoxib. PrimeC is designed to treat ALS by modulating microRNA synthesis, iron accumulation, and neuroinflammation, all of which
are hallmarks of ALS pathology. The U.S. Food and Drug Administration, or the FDA and the European Medicines Agency, or the EMA have granted
PrimeC orphan drug designation for the treatment of ALS. In addition, the EMA has granted PrimeC the Small and Medium-Sized Enterprise,
or SME, status, which offers significant potential benefits leading up to and following drug regulatory approval. We believe PrimeC&#8217;s
multifunctional mechanism of action has the potential to significantly prolong lifespan and improve ALS patients&#8217; quality of life,
thereby reducing the burden of this debilitating disease on both patients and healthcare systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">PrimeC is currently being evaluated in PARADIGM, a Phase IIb randomized,
multi-center, multinational, prospective, double-blind, placebo-controlled study, to evaluate safety, tolerability, and efficacy of PrimeC
in 68 people living with ALS. Participants were being administered PrimeC or placebo at a 2:1 ratio, respectively, for the six-month double-blind
part. Study participants were allowed to continue standard of care treatment of approved products. The primary endpoints of the study
are an evaluation of ALS-biomarkers as well as safety and tolerability assessment. Secondary and exploratory endpoints are the evaluation
of clinical efficacy (ALS Functional Rating Scale &mdash; Revised, or ALSFRS-R, and slow vital capacity), survival, and improvement in
quality of life. All subjects who completed the six-month double-blind, placebo-controlled dosing period had the opportunity to be transferred
to the PrimeC active arm for a 12-month open label extension. The study completed enrollment in May 2023, enrolling 69 participants, in
which 68 are living with ALS and one participant who was misdiagnosed for ALS and was excluded from the evaluations. Four ALS clinical
centers participated in the study in 3 territories: Israel, Italy, and Canada. In December 2023, we reported that we met the primary safety
and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of our 6-month double-blind phase
of PARADIGM. In May 2024, we announced new positive data analysis from PARADIGM clinical trial demonstrating statistically significant
slowing of disease progression in high-risk ALS patients. In July 2024, we announced results from the 12-month analysis of the PARADIGM
clinical trial which showed a significant improvement in the rate of decline of ALS Functional Rating Scale-Revised (ALSFRS-R) scores
and survival rates for subjects who received PrimeC from the start of the trial compared to those who started on placebo. In August 2024,
we announced positive 12-month biomarker data from the PARADIGM clinical trial, which showed a significant decrease in ferritin levels
and a corresponding increase in transferrin levels, both indicating alleviation of the pathology. In October 2024, we completed the full
18-month dosing in PARADIGM and announced that we anticipate reporting top-line clinical results from the full 18-month study in early
December 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Following the FDA&rsquo;s recommendation for additional non-clinical
data to support long term use of Ciprofloxacin (as PrimeC is intended for long-term administration in treating ALS) a long-term tox study
was initiated. In September 2024, we announced the successful completion of the in-life phase of the study, as we move towards the initiation
of Phase III study in the US. We had a meeting with the FDA in November 2024 and plan to meet with the EMA in the first quarter of 2025
and to subsequently commence a pivotal Phase III clinical trial for PrimeC in ALS treatment in the first half of 2025. Additionally, in
November 2023, we concluded a successful Type D meeting with the FDA regarding CMC development plans for the expected Phase 3 pivotal
study and subsequent marketing approval. The FDA endorsed our proposed CMC development plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">PrimeC was previously evaluated
in a Phase IIa clinical trial, or NST002, in 15 people living with ALS, conducted at the Tel Aviv Sourasky Medical Center, Israel. The
primary endpoint of the NST002 trial, which was safety and tolerability, was met. In this trial, the safety profile observed was consistent
with known safety profiles of ciprofloxacin and celecoxib. Side effects were mild and transient in nature. There were no new or unexpected
safety signals detected during the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, we observed
positive clinical signals in comparison to virtual controls, and a serum biomarker analysis showed significant changes following treatment,
indicating biological activity of the drug in comparison to untreated matched ALS patients. All 12 patients who completed the NST002 trial
elected to continue into an extension study with PrimeC, that was conducted as an Investigator Initiated Study. To date, we are still
supporting the drug supply for a few of the participants in this study, which is over than 40 months since NST002 was initiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We completed three additional
studies in 2022 as part of our drug development program to further support our future regulatory submissions. In April 2022, we initiated
a pharmacokinetic, or PK, study, or NCT05232461, of PrimeC. The PK open-label, randomized, single-dose, three-treatment, three-period
crossover study evaluated the effect of food on the bioavailability of PrimeC as compared to the bioavailability of co-administered ciprofloxacin
tablets and celecoxib capsules in adult subjects in the U.S. under an FDA cleared IND protocol.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In August 2022, we completed
enrollment and dosing of all subjects in a multi-dose PK study, or NCT05436678. On September 28, 2022, we released the results of the
NCT05436678 study. Based on results, we believe the PK profile of PrimeC supports the formulation&#8217;s extended-release properties,
as the concentrations of the active components have been synchronized, aiming to potentially maximize the synergism between the two compounds.
In June 2022, we reported the successful completion of the &#8220;in-life&#8221; phase of its 90-day GLP toxicology study. In this study,
the components of PrimeC, celecoxib and ciprofloxacin, were administered to rodents at doses 4x the maximal clinical dose. All animals
appeared normal, with no significant findings observed. We intend to present the data from these studies to the FDA as part of PrimeC&#8217;s
drug development plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe we have a strong
patent estate, including patents on method of use, combination, and formulation. We have secured U.S. Patent 10,980,780 relating to methods
for treatment of ALS using ciprofloxacin and celecoxib, the components of PrimeC, which expires in 2038. Equivalent patents also have
been issued in the European Patent Office, Canada, Australia, Israel and Japan. The patent estate also includes US Patent Application
18/047,289, which relates to Prime C formulations. This application was allowed by the United States Patent and Trademark Office in June
2024, and once granted, will expire in October 2042. Equivalent applications are pending in many jurisdictions worldwide. We also expect
to take advantage of orphan drug exclusivity for PrimeC, if approved, for seven years in the United States and ten years in the European
Union. In addition, U.S. patent application 16/623,467, which relates to methods of treatment of neurodegenerative disease using combinations
of ciprofloxacin and celecoxib, is currently pending. This patent application is expected to expire on June 20, 2038.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our organization is built
around a management team with extensive experience in the pharmaceutical industry, with a particular focus on ALS research and clinical
trials. We believe that our leadership team is well-positioned to lead us through clinical development, regulatory approval and commercialization
of our product candidates. Furthermore, we maintain steadfast and extensive communication and collaboration with patient advocacy groups
and associations, underscoring the importance of patient perspectives in advancing therapeutic strategies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to PrimeC, we
extended our pipeline and conducted research and development efforts for AD and PD, with a similar strategy of combined products. The
following chart represents our current product development pipeline:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 263.25pt; width: 468pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>April 2024 Registered Direct Offering</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 10, 2024, we
entered into a securities purchase agreement, or the Purchase Agreement, pursuant to which we issued and sold to an institutional
purchaser in a registered direct offering, (i) an aggregate of 1,732,000 ordinary shares, at an offering price of $1.50 per share;
and (ii) an aggregate of 1,248,000 pre-funded warrants, each representing the right to acquire one ordinary share, or the Pre-Funded
Warrants, at an offering price of $1.4999 per Pre-Funded Warrant, for gross proceeds of approximately $4.47 million before deducting
the placement agent fee and related offering expenses, which included in part the placement agent shares (the &ldquo;April 2024
Financing&rdquo;). Each Pre-Funded Warrant represented the right to purchase one ordinary share at an exercise price of $0.0001 per
share and were exercised in full. In a concurrent private placement, pursuant to the Purchase Agreement, we issued and sold to such
purchaser warrants to purchase up to an aggregate of 2,980,000 ordinary shares, which are exercisable immediately upon issuance at an exercise price of $1.50 per ordinary share and will
expire on the fifth anniversary of the original issuance date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>August 2024 Private Placement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 6, 2024, we entered into a securities purchase agreement
with certain investors, which include members of our senior management and existing investors, pursuant to which we issued and sold in
a private placement offering an aggregate of 800,000 ordinary shares and warrants to purchase an aggregate of 800,000 ordinary shares
at a combined purchase price of $0.75 per share and warrant (the &ldquo;August 2024 Financing&rdquo;). Each warrant is exercisable immediately
upon issuance at an exercise price of $0.75 per ordinary share and will expire on the fifth anniversary of the original issuance date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Standby Equity Purchase Agreement with YA</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 31, 2024, we entered
into the Purchase Agreement with YA, pursuant to which YA has committed to purchase up to $30.0 million of Advance Shares, such amount
the Commitment Amount, at our direction from time to time, subject to the restrictions and satisfaction of the conditions in the Purchase
Agreement, during the period commencing on the date of execution of the Purchase Agreement until the earlier of (i) October 31, 2027,
and (ii) YA&rsquo;s purchase of the Commitment Amount under the Purchase Agreement, such period the Commitment Period. Pursuant to the
terms of the Purchase Agreement, we have issued the Commitment Shares to YA as consideration for its irrevocable commitment to purchase
the Advance Shares under the Purchase Agreement. The Commitment Shares are also covered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus covers the
resale of up to 10,000,000 ordinary shares comprised of: (i) 224,697 ordinary shares as the Commitment Shares issued to YA; and (ii) 9,775,303
ordinary shares as Advance Shares that we have reserved for issuance and sale to YA under the Purchase Agreement from time to time during
the Commitment Period, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, if and when we determine
to sell additional ordinary shares to YA under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">YA
has no right to require us to sell any ordinary shares to YA, but YA is obligated to make purchases of the Advance Shares as
directed by us, subject to the restrictions and satisfaction of conditions set forth in the Purchase Agreement upon receipt of a
notice sent by us to YA setting forth the number of ordinary shares that we desire to issue and sell to YA, or an Advance Notice.
Actual sales of the Advance Shares to YA from time to time will depend on a variety of factors, including, among others, market
conditions, the trading price of our ordinary shares and determinations by us as to the appropriate sources of funding for us and
our operations. The purchase price of the Advance Shares that we may direct YA to purchase from time to time under the Purchase
Agreement will be equal to 97% of the lowest of the three daily VWAPs during the three consecutive trading day period
(&ldquo;Measuring Period&rdquo;) commencing on the date that we deliver any Advance Notice to YA, or the Pricing
Period.</FONT>&nbsp;&nbsp; <FONT STYLE="font-family: Times New Roman, Times, Serif">We may also specify a certain minimum acceptable
price per share in each Advance Notice. With respect to each Advance, if we notify YA of a minimum acceptable price per ordinary
share with respect to such Advance, then if the VWAP of the ordinary shares is below the minimum acceptable price indicated by us or
if there is no VWAP on any trading day during the Measuring Period, there will be an automatic reduction to the amount of the
Advance by one third for each such trading day, and that day will be excluded from the Pricing Period. The total number of ordinary shares to be issued to YA
in respect of each Advance with any excluded days will be increased by such number of ordinary shares equal to the greater of (i)
the number of ordinary shares, if any, sold by YA on such excluded days and (ii) such number of ordinary shares that Yorkville
elects to subscribe for, in each case, at a subscription price per ordinary share equal to 97% of the minimum acceptable price,
subject to the limitations set forth in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of November 18, 2024, there were 20,709,481 ordinary shares outstanding.
If all of the 10,000,000 ordinary shares offered by YA under this prospectus were issued and outstanding, such shares would represent
approximately 32.80% of the total number of ordinary shares outstanding as of November 18, 2024. The Purchase Agreement provides that
we may sell up to an aggregate of $30.0 million of ordinary shares to YA. Depending on the market prices of our ordinary shares at the
time we elect to issue such shares to YA under the Purchase Agreement, we may need to sell more ordinary shares to YA than are offered
under this prospectus to receive aggregate gross proceeds equal to the $30.0 million total commitment of YA under the Purchase Agreement,
in which case we must first register for resale under the Securities Act additional shares, which could cause additional substantial dilution
to our shareholders. The number of shares ultimately offered for resale by YA is dependent upon the number of shares we issue and sell
to YA under the Purchase Agreement.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The net proceeds under the
Purchase Agreement to us will depend on the frequency and prices at which we sell our ordinary shares, our ability to meet the conditions
set forth in the Purchase Agreement and any impacts of the Ownership Limitation (as defined below). We expect that any proceeds received
by us from such sales of ordinary shares under the Purchase Agreement will be used continued development of our pipeline products, as
well as the advancement of new programs, business development activities, and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no restrictions
on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. In addition,
YA has agreed that, during the term of the Purchase Agreement, neither YA nor its affiliates will engage in any short sales or hedging
transactions with respect to our ordinary shares, provided YA or its affiliates may (i) sell &#8220;long&#8221;, as such term is defined
in Rule 200 of Regulation SHO of the Exchange Act, the Commitment Shares and any Advance Shares issued and sold by us to YA pursuant to
an Advance Notice, and (ii) sell a number of ordinary shares equal to the number of Advance Shares that YA is unconditionally obligated
to purchase under a pending Advance Notice but has not yet received from us or our transfer agent pursuant to the Purchase Agreement,
or (i) and (ii) collectively, the Permitted Sales.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Purchase Agreement prohibits
us from directing YA to purchase ordinary shares represented by ordinary shares if those shares, when aggregated with all other shares
of our ordinary shares then beneficially owned by YA and its affiliates, would result in YA and its affiliates having beneficial ownership,
at any single point in time, of more than 4.99% of the then total outstanding ordinary shares, as calculated pursuant to Section 13(d)
of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 13d-3 thereunder, which limitation we refer to as the
Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Purchase Agreement contains
customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and
covenants were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such
agreements and may be subject to limitations agreed upon by the contracting parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Purchase Agreement will
automatically terminate upon the earliest of (i) October 31, 2027, and (ii) YA&rsquo;s purchase of the total Commitment Amount under the
Purchase Agreement. We have the right to terminate the Purchase Agreement at any time, at no cost or penalty, upon five trading days&rsquo;
prior written notice to YA, provided that (i) there are no outstanding Advance Notices, the Advance Shares under which have yet to be
issued and (ii) we have paid all amount owed to YA pursuant to the Purchase Agreement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are substantial risks
to our shareholders as a result of the sale and issuance of ordinary shares to YA under the Purchase Agreement. These risks include substantial
dilution, significant declines in our share price and our inability to draw sufficient funds when needed. See &#8220;<I>Risk Factors</I>.&#8221;
Issuances of our ordinary shares under the Purchase Agreement will not affect the rights or privileges of our existing shareholders, except
that the economic and voting interests of each of our existing shareholders will be diluted as a result of any such issuance. Although
the number of ordinary shares that our existing shareholders own will not decrease, the shares owned by our existing shareholders will
represent a smaller percentage of our total outstanding shares after any such issuances pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Nasdaq Non-Compliance</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To continue to be listed
on Nasdaq, we need to satisfy a number of conditions, including a minimum closing bid price per share of $1.00 for 30 consecutive business
days and shareholders&rsquo; equity of at least $2.5&nbsp;million. On June&nbsp;21, 2024, we received a notification letter from Nasdaq
that we had not regained compliance with Nasdaq&rsquo;s Listing Rule 5550(b) (the &ldquo;Minimum Equity Rule&rdquo;) due to our stockholders&rsquo;
equity falling below the required minimum of $2,500,000. We promptly requested a hearing before the Nasdaq Hearings Panel (the &ldquo;Panel&rdquo;),
which was held on August&nbsp;1, 2024, where we presented a comprehensive plan to regain compliance. On August&nbsp;25, 2024, we received
a written notice from Nasdaq that the Panel granted our request for an exception to continue its listing on Nasdaq until October&nbsp;31,
2024. On November 11, 2024, we received a written notice from Nasdaq stating that the Panel had granted our request for continued listing
on Nasdaq, subject to our filing a public disclosure on or before December 18, 2024, describing the transactions we had undertaken to
achieve compliance and demonstrate long-term compliance with Minimum Equity Rule and providing an indication of our equity following those
transactions and the provision of income projections to Nasdaq. This extension allows us additional time to demonstrate compliance with
the Minimum Equity Rule and meet the required conditions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Separately, on August&nbsp;26,
2024, we received a notification letter from Nasdaq notifying us that we are not in compliance with the minimum bid price requirement
set forth in Nasdaq Listing Rules for continued listing on Nasdaq, since the closing bid price for the Company&rsquo;s ordinary shares
listed on Nasdaq was below $1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain
a minimum bid price of $1.00 per share for 30 consecutive business days (the &ldquo;Minimum Bid Price Rule&rdquo;), and Nasdaq Listing
Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of
30 consecutive business days. In accordance with Listing Rule 5810(c)(3)(A), we had a period of 180 calendar days from the date of notification,
or until February&nbsp;24, 2025, to regain compliance with the Minimum Bid Price Rule. On September&nbsp;23, 2024, Nasdaq notified us
that we had regained compliance with the Minimum Bid Price Rule.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">No assurance can be given that we will be able to
regain compliance with either the Minimum Equity Rule or comply with the other standards that we are required to meet in order to maintain
a listing on such exchange, and no assurance can be given that even if we regain compliance with the Minimum Equity Rule we will maintain
sufficient shareholders&#8217; equity, or alternatively that the price of the ordinary shares will not again be in violation of Nasdaq&#8217;s
Minimum Bid Price Rule in the future. Our failure to meet these requirements may result in our securities being delisted from Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our legal and commercial name
is NeuroSense Therapeutics Ltd. We were incorporated on February&nbsp;13, 2017 and were registered as a private company limited by shares
under the laws of the State of Israel. We completed our initial public offering on the Nasdaq in December&nbsp;2021. Our ordinary shares
and warrants to purchase our ordinary shares are traded on the Nasdaq under the symbol &#8220;NRSN&#8221; and &#8220;NRSNW,&#8221; respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our principal executive offices
are located at 11 HaMenofim Street, Building B, Herzliya, 4672562 Israel, and our telephone number is +972-9-7996183. Our website address
is&nbsp;<I>www.neurosense-tx.com</I>. The information on our website does not constitute a part of this prospectus. Our agent for service
of process in the United&nbsp;States is Cogency Global Inc., 122 East 42<SUP>nd</SUP>&nbsp;Street, 18<SUP>th</SUP>&nbsp;Floor, New&nbsp;York,
NY&nbsp;10168.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being an Emerging Growth Company</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">As a company with less than $1.235&nbsp;billion
in revenue during our last fiscal year, we are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups
Act&nbsp;of&nbsp;2012 (the &#8220;JOBS Act&#8221;). As such, we may take advantage of certain exemptions from various reporting requirements
that are applicable to other publicly traded entities that are not emerging growth companies. These exemptions include:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">not being required to have our registered independent public
accounting firm attest to management&#8217;s assessment of our internal control over financial reporting;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">not being required to comply with any requirement that may
be adopted by the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;), regarding mandatory audit firm rotation or a supplement
to the auditor&#8217;s report providing additional information about the audit and the financial statements (i.e., an auditor discussion
and analysis);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">not being required to submit certain executive compensation
matters to stockholder advisory votes, such as &#8220;say-on-pay,&#8221; &#8220;say-on-frequency&#8221; and &#8220;say-on-golden&nbsp;parachutes&#8221;;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">the audit reports of our independent registered public accounting
firm do not require communication of critical audit matters; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">not being required to disclose certain executive compensation
related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#8217;s
compensation to median employee compensation.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a result, the information contained in this prospectus
and the documents incorporated by reference herein may be different from the information you receive from other public companies in which
you hold shares. We may take advantage of these provisions for up until we are no longer an emerging growth company. We would cease to
be an emerging growth company upon the earliest to occur of: (i)&nbsp;the last&nbsp;day of the first fiscal year in which our annual gross
revenues exceed $1.235&nbsp;billion; (ii)&nbsp;the date on which we have issued more than $1&nbsp;billion in non-convertible&nbsp;debt
securities during the previous three&nbsp;years; (iii)&nbsp;the date on which we are deemed to be a &#8220;large accelerated filer&#8221;
as defined in Rule&nbsp;12b-2&nbsp;under the Exchange&nbsp;Act; or (iv)&nbsp;the last&nbsp;day of the fiscal year following the fifth
anniversary of our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being a Foreign Private Issuer</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are also a non-U.S.&nbsp;company with foreign
private issuer status. Even after we no longer qualify as an emerging growth company, as long as we continue to qualify as a foreign private
issuer under the Exchange&nbsp;Act, we will be exempt from certain provisions of the Exchange&nbsp;Act that are applicable to U.S.&nbsp;domestic
public companies, including:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">the sections of the Exchange Act regulating the solicitation
of proxies, consents or authorizations in respect of a security registered under the Exchange Act;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">the sections of the Exchange Act requiring insiders to file
public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period
of time; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD><TD STYLE="text-align: justify">the rules under the Exchange Act requiring the filing with
the SEC of quarterly reports on Form 10-Q&nbsp;containing unaudited financial statements and other specified information, and current
reports on Form&nbsp;8-K&nbsp;upon the occurrence of specified significant events.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Notwithstanding these exemptions, we will file with
the SEC, within four&nbsp;months after the end of each fiscal year, or such applicable time as required by the SEC, an Annual Report on
Form&nbsp;20-F&nbsp;containing financial statements audited by an independent registered public accounting firm.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may take advantage of these exemptions until
such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of
our outstanding voting securities are held by U.S.&nbsp;residents and any of the following three circumstances applies: (i)&nbsp;the majority
of our executive officers or directors are U.S.&nbsp;citizens or residents; (ii)&nbsp;more than 50% of our assets are located in the U.S.;
or (iii)&nbsp;our business is administered principally in the U.S.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Both foreign private issuers and emerging growth
companies also are exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an
emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures
required of companies that are neither an emerging growth company nor a foreign private issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 28%"><FONT STYLE="font-size: 10pt"><B>Ordinary Shares Outstanding Prior to this Offering</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-size: 10pt">20,709,481 ordinary shares (as of November 18, 2024, which such number of ordinary shares includes the Commitment Shares).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><B>Securities Offered by the Selling Shareholder</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10,000,000 ordinary shares, represented as (i) 224,697 ordinary shares issued as the Commitment Shares on the date of execution of the Purchase Agreement; and (ii) 9,775,303 ordinary shares as the Advance Shares that we may sell to YA under the Purchase Agreement from time to time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><B>Ordinary Shares Outstanding Immediately After this Offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">30,484,784 ordinary shares, assuming the issuance of 9,775,303 ordinary shares as the Advance Shares. The actual number of ordinary shares will vary depending upon the number of ordinary shares represented by ordinary shares we sell under the Purchase Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We will not receive any proceeds from the sale of the YA Shares included in this prospectus by the Selling Shareholder. We may receive up to $30.0 million aggregate gross proceeds under the Purchase Agreement from sales of ordinary shares that we elect to make to YA as Advance Shares pursuant to the Purchase Agreement, if any, from time to time in our sole discretion, although the actual amount of proceeds that we may receive cannot be determined at this time and will depend on the number of ordinary shares we sell under the Purchase Agreement and market prices at the times of such sales. Any proceeds that we receive from sales of ordinary shares under the Purchase Agreement will be used for continued development of our pipeline products, as well as the advancement of new programs, business development activities, and general corporate purposes. See &#8220;Use of Proceeds.&#8221;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Investing in our securities involves a high degree of risk. You should read the &#8220;Risk Factors&#8221; section starting on page 9 of this prospectus and &#8220;Item 3. - Key Information &#8211; D. Risk Factors&#8221; in our Annual Report on Form 20-F for the fiscal year ended December 31, 2023, or the 2023 Annual Report, incorporated by reference herein, and other information included or incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in our securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><B>Nasdaq Capital Market symbol</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;NRSN&#8221;.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise stated, all
information in this prospectus is based on 20,709,481 Ordinary Shares outstanding as of November 18, 2024, and does not include the
following as of that date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1,069,128 ordinary shares issuable upon the exercise of options outstanding, at a weighted average exercise price of $2.31 per share under our 2018 Employee Share Option Plan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">218,000 ordinary shares issuable upon the vesting of restricted share units outstanding, some of which are under our 2018 Share Incentive Plan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">848,705 ordinary shares reserved for issuance and available for future grant under our 2018 Share Incentive Plan;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">8,535,000 ordinary shares underlying warrants with a weighted average exercise price of $2.38 per share, and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Advance Shares registered under the registration statement to which
this prospectus relates and any additional shares we may issue to YA pursuant to the Purchase Agreement should we elect to sell such
shares to YA.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>



<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>You should carefully consider
the risks described below and the risks described in our 2023 Annual Report, which are incorporated by reference herein, as well as the
financial or other information included in this prospectus or incorporated by reference in this prospectus, including our consolidated
financial statements and the related notes, before you decide to buy our securities. The risks and uncertainties described below are not
the only risks facing us. We may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial.
Any of the risks described below, and any such additional risks, could materially adversely affect our business, financial condition or
results of operations. In such case, you may lose all or part of your original investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Related to the Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>It is not possible to predict the actual
number of shares we will sell under the Purchase Agreement to the Selling Shareholder, or the actual gross proceeds resulting from those
sales.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 31, 2024, we entered
into the Purchase Agreement with YA, pursuant to which YA has committed to purchase up to $30.0 million in ordinary shares, subject to
certain limitations and conditions set forth in the Purchase Agreement. The ordinary shares that may be issued under the Purchase Agreement
may be sold by us to YA at our discretion from time to time during the Commitment Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We generally have the right
to control the timing and amount of any sales of our ordinary shares to YA under the Purchase Agreement. Sales of our ordinary shares,
if any, to YA under the Purchase Agreement will depend upon market conditions and other factors. We may ultimately decide to sell to YA
all, some or none of the ordinary shares that may be available for us to sell to YA pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because the purchase
price per share to be paid by YA for the ordinary shares that we may elect to sell to YA under the Purchase Agreement, if any, will
fluctuate based on the market prices of our ordinary shares during the applicable Pricing Period for each purchase made pursuant to
the Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales,
the number of ordinary shares that we will sell to YA under the Purchase Agreement, the purchase price per share that YA will pay
for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases
by YA under the Purchase Agreement, if any.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Limitations in the Purchase
Agreement, including the Ownership Limitation, and our ability to meet the conditions necessary to deliver an Advance Notice, could prevent
us from being able to raise funds up to the Commitment Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, although the Purchase
Agreement provides that we may sell up to an aggregate of $30.0 million of our ordinary shares to YA, only 10,000,000 ordinary shares
are being registered for resale by YA under the registration statement that includes this prospectus, consisting of (i) the Commitment
Shares that we issued to YA upon execution of the Purchase Agreement as consideration for its commitment to purchase our ordinary shares
under the Purchase Agreement, and (ii) the Advance Shares that we may elect to sell to YA, in our sole discretion, from time to time from
during the Commitment Period, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, through sales
under the Purchase Agreement. Even if we elect to sell to YA all of the shares being registered for resale under this prospectus, depending
on the market prices of our ordinary shares at the time of such sales, the actual gross proceeds from the sale of all such shares may
be substantially less than the $30.0 million Commitment Amount under the Purchase Agreement, which could materially adversely affect our
liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we desire to issue and
sell to YA under the Purchase Agreement more than the a number of ordinary shares in excess of the YA Shares being registered for resale
under this prospectus, and the Ownership Limitation and other limitations in the Purchase Agreement would allow us to do so, we would
need to file with the SEC one or more additional registration statements to register under the Securities Act the resale by YA of any
such additional ordinary shares and the SEC would have to declare such registration statement or statements effective before we could
sell additional ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any issuance and sale by us
under the Purchase Agreement of a substantial amount of ordinary shares in addition to the ordinary shares being registered for resale
by YA under this prospectus could cause additional substantial dilution to our shareholders. The number of our ordinary shares ultimately
offered for sale by YA is dependent upon the ordinary shares, if any, we ultimately sell to YA under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The resale by YA of a significant
amount of shares registered for resale in this offering at any given time, or the perception that these sales may occur, could cause the
market price of our ordinary shares to decline and to be highly volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investors who buy shares at different times
will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Purchase Agreement,
we will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold to YA. If and when we do elect
to sell ordinary shares to YA pursuant to the Purchase Agreement, YA may resell all, some or none of such shares at any time or from time
to time in its discretion and at different prices. As a result, investors who purchase shares from YA in this offering at different times
will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution
and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from YA
in this offering as a result of future sales made by us to YA at prices lower than the prices such investors paid for their shares in
this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may require additional financing to sustain
our operations and without it we will not be able to continue operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The extent to which we
rely on YA as a source of funding will depend on a number of factors, including the prevailing market price of our ordinary shares,
our ability to meet the conditions necessary to deliver Advance Notices under the Purchase Agreement, the impacts of the Ownership
Limitation and the extent to which we are able to secure funding from other sources. Regardless of the amount of funds we ultimately
raise under the Purchase Agreement, if any, we expect to continue to seek other sources of funding. Even if we were to sell to YA
the total Commitment Amount under the Purchase Agreement, we expect that we will need additional capital to fully implement our
business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The sale of a substantial amount of our
ordinary shares or ordinary shares, including resale of the held by the selling shareholder in the public market could adversely affect
the prevailing market price of our ordinary shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are registering for resale
10,000,000 ordinary shares. Sales of substantial amounts of shares of our ordinary shares or ordinary shares in the public market, or
the perception that such sales might occur, could adversely affect the market price of our ordinary shares, and the market value of our
other securities. We cannot predict if and when the selling shareholder may sell such shares in the public markets. Furthermore, in the
future, we may issue additional ordinary shares or ordinary shares or other equity or debt securities convertible into ordinary shares
or ordinary shares. Any such issuance could result in substantial dilution to our existing shareholders and could cause our share price
to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Future sales and
issuances of our ordinary shares or other securities might result in significant dilution and could cause the price of our ordinary shares
to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">To
raise capital, we may sell ordinary shares, convertible securities or other equity securities in one or more transactions other than those
contemplated by the Purchase Agreement, at prices and in a manner we determine from time to time. We may sell shares or other securities
in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing
shares or other securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional
ordinary shares, or securities convertible or exchangeable into ordinary shares, in future transactions may be higher or lower than the
price per share paid by investors in this offering. Any sales of additional shares will dilute our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Sales
of a substantial number of ordinary shares in the public market or the perception that these sales might occur could depress the market
price of our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable
to predict the effect that sales may have on the prevailing market price of our ordinary shares. In addition, the sale of substantial
numbers of our ordinary shares could adversely impact their price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Management will
have broad discretion as to the use of the net proceeds from the Purchase Agreement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Our
management will have broad discretion in the allocation of the net proceeds and could use them for purposes other than those contemplated
at the time of this offering. Accordingly, you will be relying on the judgment of our management with regard to the use of those net proceeds,
and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
It is possible that, pending their use, we may invest those net proceeds in a way that does not yield a favorable, or any, return for
us. The failure of our management to use such funds effectively could have a material adverse effect on our business, financial condition,
operating results and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We conduct some of our operations in Israel.
Conditions in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel&#8217;s war
against them, may affect our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our corporate headquarters
is located in Herzliya, Israel. Because we are incorporated under the laws of the State of Israel, and most of our officers and fourteen
out of sixteen of our employees are residents of Israel, our business and operations are directly affected by economic, political, geopolitical
and military conditions in Israel. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between
Israel and its neighboring countries and terrorist organizations active in the region. These conflicts have involved missile strikes,
hostile infiltrations and terrorism against civilian targets in various parts of Israel, which have negatively affected business conditions
in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2023, Hamas
terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military
targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s
border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and
injuries, and Hamas additionally kidnapped many Israeli civilians and soldiers.&nbsp;Following the attack, Israel&#8217;s security
cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their
continued rocket and terror attacks. In parallel, border clashes between Israel and the Hezbollah terrorist group on Israel&#8217;s
northern border with Lebanon intensified and may escalate into a greater regional conflict.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, since the commencement
of these events, there have been continued hostilities along Israel&#8217;s northern border with Lebanon (with the Hezbollah terror organization)
<FONT STYLE="background-color: white">and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various
rebel militia groups in Syria and Iraq</FONT>. In addition, in April 2024 and October 2024, Iran (in concert with other regional actors)
launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely
believed to be developing nuclear weapons. Such attacks may continue due to continuing tensions in the region. Iran is also believed to
have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen
and various rebel militia groups in Syria and Iraq. These situations may potentially escalate in the future to more violent events which
may affect Israel and us. Additionally, Yemeni rebel group, the Houthis, launched series of attacks on global shipping routes in the Red
Sea, causing disruptions of supply chain. These geopolitical developments may adversely affect our ability to continue carrying out various
administrative, research, operational and commercial functions and activities both in Israel and globally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any hostilities, armed conflicts,
terrorist activities involving Israel or the interruption or curtailment of trade between Israel and its trading partners, or any political
instability in the region could directly or indirectly adversely affect business conditions and our results of operations and could make
it more difficult for us to raise capital and could adversely affect the market price of our ordinary share. An escalation of tensions
or violence might result in a significant downturn in the economic or financial condition of Israel, which could have a material adverse
effect on our operations in Israel and our business. Parties with whom we do business have sometimes declined to travel to Israel during
periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to meet our business partners
face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving
performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure
provisions in such agreements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Israel Defense Force,
or IDF, the national military of Israel, is a conscripted military service, subject to certain exceptions. Since October 7, 2023, the
IDF has called up several hundred thousand of its reserve forces to serve. Fourteen out of our current 16 employees are resident in Israel.
Three of our five executive officers and the 11 other non-management employees of the Company reside in Israel. Currently none of our
executive officers nor non-management employees have been called up to perform reserve military service; however, some employees may be
called for service in the current or future wars or other armed conflicts with Hamas, Hezbollah or other regional threat actors, and such
persons may be absent for an extended period of time. As a result, our operations in Israel may be disrupted by such absences, which disruption
may materially and adversely affect our business, prospects, financial condition and results of operations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since the war broke out on
October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced disruptions to our clinical
studies. As such, our clinical and business development activities remain on track. However, the intensity and duration of Israel&#8217;s
current war against Hamas and Hezbollah is difficult to predict at this stage, as are such war&#8217;s economic implications on our business
and operations and on Israel&#8217;s economy in general. If the war extends for a long period of time or expands to other fronts, such
as Iran, Lebanon, Syria and the West Bank, our operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All of
our&nbsp;clinical and pre-clinical&nbsp;research and development is&nbsp;currently&nbsp;being conducted outside of
Israel,&nbsp;other than our 12-month open&nbsp;label-extension, or OLE, study of the PARADIGM trial,&nbsp;partially conducted in
Tel&nbsp;Aviv,&nbsp;and a&nbsp;planned&nbsp;Phase 2 trial&nbsp;with PrimeC&nbsp;for&nbsp;AD that we plan to conduct in Haifa,
Israel. The OLE has not been affected by the war, although the quality of the study may be adversely affected if as a result of the
war patients are unable to visit the study center or the study coordinator is not able to conduct home visits and monitor
the&nbsp;patients. In addition, in the event of a significant escalation of hostilities in northern Israel, there may be a delay in
the&nbsp;planned&nbsp;AD trial.&nbsp;We do not believe the planned AD trial will be materially affected by the war and do not
anticipate that any such delay as a result of the war would have a material impact on us. We may also elect to set up a site in
Israel for a Phase 3 pivotal ALS trial of PrimeC, but this would be in addition to numerous other sites in Europe and the United
States, and as a result we do not expect the timeline or quality of this trial to be adversely affected by the war. Our
manufacturing is conducted in India. We do not currently anticipate any disruption to the supply chain relevant to our ongoing
clinical trials and believe there are alternative sources of supply from whom we could obtain the necessary finished drug product to
conduct our clinical trials. In addition, we believe we have sufficient finished product in inventory to continue our ongoing
clinical trials for at least the next few months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial insurance does
not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli
government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of
war, there can be no assurance that this government coverage will be maintained, or if maintained, will be sufficient to compensate us
fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Finally, political conditions
within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023, the
Israeli government pursued extensive changes to Israel&#8217;s judicial system, which sparked extensive political debate and unrest. To
date, these initiatives have been substantially put on hold. Actual or perceived political instability in Israel or any negative changes
in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial
condition, results of operations and growth prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to maintain compliance with NASDAQ&#8217;s
continued listing requirements, our shares may be delisted from the NASDAQ Capital Market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To continue to be listed
on Nasdaq, we need to satisfy a number of conditions, including the Minimum Bid Price Rule and the Minimum Equity Rule. On June&nbsp;21,
2024, we received a notification letter from Nasdaq that we had not regained compliance with the Minimum Equity Rule due to our stockholders&rsquo;
equity falling below the required minimum of $2,500,000. We promptly requested a hearing before the Panel, which was held on August&nbsp;1,
2024, where we presented a comprehensive plan to regain compliance. On August&nbsp;25, 2024, we received a written notice from Nasdaq
that the Panel granted our request for an exception to continue its listing on Nasdaq until October&nbsp;31, 2024. On November 11, 2024,
we received a written notice from Nasdaq, stating that the Panel had granted our request for continued listing on Nasdaq, subject to our
filing a public disclosure on or before December 18, 2024, describing the transactions we had undertaken to achieve compliance and demonstrate
long-term compliance with Minimum Equity Rule and providing an indication of our equity following those transactions and the provision
of income projections to Nasdaq. This extension allows us additional time to demonstrate compliance with the Minimum Equity Rule and meet
the required conditions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No assurance can be given that
we will be able to regain compliance with the Minimum Equity Rule or comply with the other standards that we are required to meet in order
to maintain a listing on such exchange, such as the Minimum Bid Price Rule, and no assurance can be given that even if we regain compliance
with the Minimum Equity Rule we will maintain sufficient shareholders&#8217; equity or the price of the ordinary shares will not again
be in violation of Nasdaq&#8217;s Minimum Bid Price Rule in the future. Our failure to meet these requirements may result in our securities
being delisted from Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the ordinary shares are
delisted from Nasdaq, we may seek to list them on other markets or exchanges or the ordinary shares may trade on the pink sheets. In the
event of such delisting, our shareholders&#8217; ability to trade, or obtain quotations of the market value of, our ordinary shares would
be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger
spreads in the bid and ask prices for our securities. In addition, the substantially decreased trading in the ordinary shares and decreased
market liquidity of the ordinary shares as a result of the loss of market efficiencies associated with Nasdaq and the loss of federal
preemption of state securities laws, which could materially adversely affect our ability to obtain financing on acceptable terms, if at
all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development
opportunities. Additionally, the market price of the ordinary shares may decline further and shareholders may lose some or all of their
investment. There can be no assurance that the ordinary shares, if delisted from Nasdaq in the future, would be listed on another national
or international securities exchange or on a national quotation service, the Over-The-Counter&nbsp;Markets or the pink sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>USE OF PROCEEDS</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus relates to
our ordinary shares represented by ordinary shares that may be offered and sold from time to time by YA. All of our ordinary shares offered
by the Selling Shareholder pursuant to this prospectus will be sold by the Selling Shareholder for its own account. We will not receive
any of the proceeds from these sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may receive up to $30.0
million aggregate gross proceeds under the Purchase Agreement from any sales of ordinary shares we make to YA pursuant to the Purchase
Agreement. However, we are unable to estimate the actual amount of proceeds that we may receive, as it will depend on the number of ordinary
shares that we choose to sell, our ability to meet the conditions to purchases set forth in the Purchase Agreement, market conditions
and the price of our ordinary shares, among other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We currently intend to use
the net proceeds from the sale of securities under the Purchase Agreement to advance the clinical development of our lead product candidate,
PrimeC for ALS, for the clinical development and preclinical research and development in support of potential investigational new drug
applications for, CogniC for AD, StabiliC for PD, and for other new assets or indications, for future research and development of new
product candidates and for working capital and general corporate purposes. The timing and amount of our actual expenditures will be based
on many factors, and we cannot specify with certainty all of the particular uses of the net proceeds from this offering. Accordingly,
our management will have significant discretion and flexibility in applying the net proceeds of this offering. We have no current commitments
or binding agreements with respect to any material acquisition of or investment in any technologies, products or companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our expected use of net proceeds
under the Purchase Agreement represents our current intentions based on our present plans and business condition, which could change in
the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty any or all
of the particular uses for the net proceeds to be received under the Purchase Agreement, or the amounts, if any, that we will actually
spend on the uses set forth above. The amounts and timing of our actual use of the net proceeds may vary depending on numerous factors,
including our ability to obtain additional financing and changes we may make to our development plan. As a result, our management will
have broad discretion in the application of the net proceeds, which may include uses not set forth above, and investors will be relying
on our judgment regarding the application of the net proceeds from this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pending the use of the net
proceeds from this offering as described above, we intend to invest the net proceeds in a variety of capital preservation investments,
short and intermediate term, interest-bearing, investment-grade instruments, U.S. government securities and highly rated corporate debt
securities, although our investment policy may change following the date of this prospectus supplement. It is possible that, pending their
use, we may invest the net proceeds in a way that does not yield a favorable, or any, return for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">The table below sets forth our total capitalization:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">on an actual basis as of June&nbsp;30, 2024;</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">on a pro forma basis, giving effect to (i) the sale of an aggregate of
947,778 ordinary shares at an average price of $1.13 per ordinary share, for aggregate gross proceeds of $1,070 thousand (net proceeds
of approximately $1,038 thousand, after deducting sales agent fees and estimated aggregate offering expenses payable by us); (ii) the
issuance of 616,000 ordinary shares as a result of exercise of 616,000 pre-funded&nbsp;warrants; (iii) the issuance of 66,000 ordinary
shares as a result of vested RSUs; and (iv) the issuance in the August 2024 financing of 800,000 ordinary shares and warrants to purchase
an aggregate of 800,000 ordinary shares resulting in net proceeds of $600 thousand; and</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">on a pro forma as adjusted basis, giving further effect to (i) the
issuance of 224,697 ordinary shares as the Commitment Shares and (ii) the issuance and sale of 9,775,303 ordinary shares as Advance Shares,
at an assumed offering price of $1.18 per ordinary share, which is the last reported sales price of our ordinary shares on the Nasdaq
on November 18, 2024, assuming the equity line will be partially utilized by us, after deducting the estimated offering expenses by us
resulting in net proceeds of $11,104 thousand.</P>




<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table should be read in conjunction
with &#8220;Use of Proceeds,&#8221; our financial statements and related notes that are incorporated by reference into this prospectus
and the other financial information included or incorporated by reference into this prospectus. Our historical results do not necessarily
indicate our expected results for any future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
amounts shown below are unaudited, represent management&rsquo;s estimate, and their accounting treatment has not been completed. In the
pro forma as adjusted column, the company assumes that any derivative assets arising from this issuance is equal to zero, and therefore,
the fair value of the 224,697 Commitment Shares issued is recognized as an expanse</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.
</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As&nbsp;of&nbsp;June 30, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B><I>(unaudited)</I></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual<BR> (in&nbsp;thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma<BR> (in&nbsp;thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma<BR> As&nbsp;Adjusted<BR> (in&nbsp;thousands)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,208</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,846</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,950</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Long term liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Shareholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">Ordinary shares, no par value per share</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Share premium and capital reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,679</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,317</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,702</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(32,382</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(32,382</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(32,663</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,703</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(65</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total capitalization</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,667</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(29</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,075</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The number of the ordinary
shares to be issued and outstanding immediately after this offering as shown above assumes that all of the ordinary shares offered hereby
are sold and is based on 18,055,006 ordinary shares issued and outstanding as of June 30, 2024. This number excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,060,128 ordinary shares issuable upon the exercise of options
outstanding, at a weighted average exercise price of $2.31 per share under our 2018 Employee Share Option Plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">284,000 ordinary shares issuable upon the vesting of restricted
share units outstanding, some of which are under our 2018 Share Incentive Plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">848,705 ordinary shares reserved for issuance and available
for future grant under our 2018 Share Incentive Plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">8,535,000 ordinary shares underlying warrants with a weighted
average exercise price of $2.38 per share; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the Commitment Shares and the Advance Shares registered under
the registration statement to which this prospectus relates and any additional shares we may issue to YA pursuant to the Purchase Agreement
should we elect to sell such shares to YA.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>SELLING SHAREHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus relates to
the possible resale from time to time by YA of any or all of the ordinary shares that are to be issued by us to YA under the Purchase
Agreement. For additional information regarding the issuance of ordinary shares covered by this prospectus, see the section titled &#8220;Prospectus
Summary&#8212;Standby Equity Purchase Agreement with YA&#8221; above. Except for the transactions contemplated by the Purchase Agreement,
YA does not, and has not had, any material relationship with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below presents information
regarding the Selling Shareholder and the shares ordinary shares that it may offer from time to time under this prospectus. This table
is prepared based on information supplied to us by the Selling Shareholder. The number of shares in the column &#8220;Maximum Number of
Ordinary Shares to be Offered Pursuant to this Prospectus&#8221; represents all of the ordinary shares that the Selling Shareholder may
offer under this prospectus. The Selling Shareholder may sell some, all or none of its shares in this offering. We do not know how long
the Selling Shareholder will hold the shares before selling them, and we currently have no agreements, arrangements or understandings
with the Selling Shareholder regarding the sale of any of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The beneficial ownership of
our ordinary shares is determined in accordance with the rules of the SEC. See &#8220;Principal Shareholders&#8221; for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The percentage of ordinary
shares beneficially owned by the Selling Shareholder prior to the offering shown in the table below is based on an aggregate of on 20,436,784
ordinary shares outstanding on November 18, 2024. The number of ordinary shares that may actually be sold by us under the Purchase Agreement
may be fewer than the number of ordinary shares being offered by this prospectus. The fourth column assumes the sale of all of the ordinary
shares offered by the Selling Shareholder pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Ordinary Shares<BR> Owned Prior to Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Maximum Number of Ordinary Shares to be Offered Pursuant to</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Ordinary Shares<BR> Owned After Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><B>Name of Selling Shareholder</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>this&nbsp;Prospectus <SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number<SUP>(3)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-size: 10pt">YA II PN, LTD.<SUP>(4)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">224,697</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">10,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents ownership of less
than 1%.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This number represents the 224,697 ordinary shares that we issued to YA
as the Commitment Shares in consideration for entering into the Purchase Agreement with us. In accordance with Rule 13d-3(d) under the
Exchange Act, we have excluded from the number of ordinary shares beneficially owned prior to the offering all of the ordinary shares
that YA may be required to purchase under the Purchase Agreement, because the issuance of such ordinary shares is solely at our discretion
and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of YA&rsquo;s control,
including the registration statement that includes this prospectus becoming and remaining effective.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Although the Purchase Agreement provides that we may sell up to $30
    million of our ordinary shares to YA, we are only registering 10,000,000 ordinary shares for resale under this prospectus, including
    the Commitment Shares we have issued to YA, in consideration of YA&#8217;s obligation to purchase ordinary shares at our direction
    under the Purchase Agreement and, for which we will receive no cash proceeds. Therefore, only 9,775,303 of such ordinary shares
    represent shares that we may issue and sell to YA for cash consideration in purchases under the Purchase Agreement from time to
    time, at our sole discretion, during the 36-month period. Depending on the price per ordinary shares at which we sell the Advance
    Shares to YA pursuant to the Purchase Agreement, we may need to sell to YA under the Purchase Agreement more ordinary shares than
    are offered under this prospectus in order to receive aggregate gross proceeds equal to the $30.0 million Commitment Amount under
    the Purchase Agreement. If we choose to do so and otherwise satisfy the conditions in the Purchase Agreement, we must first register
    for resale under the Securities Act such additional ordinary shares. The number of ordinary shares ultimately offered for resale by
    YA is dependent upon the number of ordinary shares we sell to YA under the Purchase Agreement.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">(3)</TD><TD STYLE="text-align: justify">Assumes the sale of all ordinary shares being offered pursuant
to this prospectus.</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">(4)</TD><TD STYLE="text-align: justify">YA is a fund managed by Yorkville Advisors Global, LP (&ldquo;Yorkville
LP&rdquo;). Yorkville Advisors Global II, LLC (&ldquo;Yorkville LLC&rdquo;) is the General Partner of Yorkville LP. All investment decisions
for YA are made by Yorkville LLC&rsquo;s President and Managing Member, Mr. Mark Angelo. The business address of YA is 1012 Springfield
Avenue, Mountainside, NJ 07092.</TD>
</TR></TABLE>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 31, 2024, we entered
into the Purchase Agreement with YA. The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein,
YA is committed to purchase up to $30 million in ordinary shares during the Commitment Period. From time to time, and at our sole discretion,
we may present YA with Advance Notices to purchase our ordinary shares. The ordinary shares would be purchased pursuant to the Purchase
Agreement at 97% of the lowest of the three daily VWAPs during the applicable Pricing Period as set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The ordinary shares offered
by this prospectus are being offered by the Selling Shareholder. The Selling Shareholder is an &#8220;underwriter&#8221; within the meaning
of Section 2(a)(11) of the Securities Act. We have agreed in the Purchase Agreement to provide customary indemnification to YA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">It is possible that our shares
may be sold from time to time by YA in one or more of the following manners:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary brokerage transactions and transactions in which the broker solicits purchasers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a block trade in which the broker or dealer so engaged will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to a broker-dealer as principal and resale by the broker-dealer for its account; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a combination of any such methods of sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YA has agreed that, during
the term of the Purchase Agreement, neither YA or its affiliates will engage in any short sales or hedging transactions with respect to
our ordinary shares, provided that YA and its affiliates may enter into Permitted Sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YA and any unaffiliated broker-dealer
will be subject to liability under the federal securities laws and must comply with the requirements of the Exchange Act, including without
limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales
of ordinary shares by YA or any unaffiliated broker-dealer. Under these rules and regulations, YA and any unaffiliated broker-dealer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">may not engage in any stabilization activity in connection with our securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">must furnish each broker which offers our ordinary shares covered by the prospectus and accompanying prospectus that are a part of our Registration Statement with the number of copies of such prospectus and accompanying prospectus which are required by each broker; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than as permitted under the Exchange Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These restrictions may affect
the marketability of the ordinary shares by YA and any unaffiliated broker-dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have advised YA that it
is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the Selling
Shareholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or
purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the
entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security
in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will pay the expenses incident
to the registration under the Securities Act of the offer and sale of our ordinary shares covered by this prospectus by the Selling Shareholder.
We estimate that our total expenses for the offering will be approximately $85,000 (excluding the Commitment Shares). As consideration
for its irrevocable commitment to purchase our ordinary shares under the Purchase Agreement, we issued the Commitment Shares to the Selling
Shareholder, calculated as 1% of the Commitment Amount. We also paid a $25,000 structuring fee to an affiliate of the Selling Shareholder
in connection with entry into the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The securities to be registered for resale on this
registration statement on Form&nbsp;F-1&nbsp;of which this prospectus forms a part include up to an aggregate amount of 10,000,000&nbsp;Ordinary
Shares offered for resale by the selling shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ordinary Shares</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our authorized share capital
consists of 90,000,000&nbsp;ordinary shares, no par value per share, of which 20,709,481 ordinary shares were issued and outstanding as
of November 18, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All of the outstanding ordinary shares are validly
issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any pre-emptive&nbsp;rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Voting Rights and Conversion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All ordinary shares will have identical voting and
other rights in all respects. None of our major shareholders have different voting rights than our other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Transfer of Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Fully paid ordinary shares are issued in registered
form and may be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited
by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trading. The ownership or voting
of ordinary shares by non-residents&nbsp;of Israel is not restricted in any way by the amended and restated articles of association or
the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Liability to Further Capital Calls</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors may make, from time to time,
such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to ordinary shares held by such shareholders,
which is not payable at a fixed time. Such shareholder shall pay the amount of every call so made upon him. Unless otherwise stipulated
by our board of directors, each payment in response to a call shall be deemed to constitute a pro rata payment on account of all shares
with respect to which such call was made. A shareholder shall not be entitled to his rights as shareholder, including the right to dividends,
unless such shareholder has fully paid all the notices of call delivered to him, or which according to our amended and restated articles
of association are deemed to have been delivered to him, together with interest, linkage and expenses, if any, unless otherwise determined
by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under our amended and restated articles of association,
we may not engage in any &#8220;business combinations&#8221; with any &#8220;interested shareholder&#8221; for a three-year&nbsp;period
following the time that such shareholder became an interested shareholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">prior to the time that such shareholder became an interested
shareholder, our board of directors approved either the business combination or the transaction which resulted in the shareholder becoming
an interested shareholder;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">upon consummation of the transaction which resulted in the
shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of our voting shares outstanding at the
time the transaction commenced, excluding for purposes of determining our voting shares outstanding (but&nbsp;not the outstanding voting
shares owned by the interested shareholder) those shares owned by persons who are directors and also officers; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">at the time that such shareholder became an interested shareholder,
or subsequent to such time, the business combination is approved by our board of directors and authorized at a general meeting of shareholders
by the affirmative vote of at least 66<SUP>2/3</SUP>% of our voting shares outstanding that are not owned by the interested shareholder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, a &#8220;business combination&#8221;
includes any merger, consolidation, sale or other transaction resulting in a financial benefit to the interested shareholder. Subject
to certain exceptions, an &#8220;interested shareholder&#8221; is any person (other than us and any of our direct or indirect majority-owned&nbsp;subsidiaries)
who, together with such person&#8217;s affiliates and associates, owns, or within the previous three&nbsp;years owned, 15% or more of
our voting shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under certain circumstances, this provision will
make it more difficult for a person who would be an &#8220;interested shareholder&#8221; to effect various business combinations with
a corporation for a three-year&nbsp;period. This provision may encourage companies interested in acquiring us to negotiate in advance
with our board of directors because the shareholder approval requirement would be avoided if our board of directors approves either the
business combination or the transaction which results in the shareholder becoming an interested shareholder. These provisions also may
have the effect of preventing changes in our board of directors and may make it more difficult to accomplish transactions which shareholders
may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Election of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ordinary shares do not have cumulative voting
rights for the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders meeting
have the power to elect our directors, subject to the special approval requirements for external directors under the Companies Law. Under
our amended and restated articles of association, the number of directors on our board of directors must be no less than three and no
more than nine, including any external directors required to be appointed under the Companies Law. The minimum and maximum number of directors
may be changed, at any time and from time to time, by a special vote of the holders of at least 66&#8532;% of the outstanding shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than external directors, for whom special
election requirements apply under the Companies Law, the vote required to appoint a director is a simple majority vote. In addition, under
our amended and restated articles of association, our board of directors may elect new directors to fill vacancies (whether such vacancy
is due to a director no longer serving or due to the number of directors serving being less than the maximum required in our amended and
restated articles of association), provided that the total number of directors shall not, at any time, exceed nine directors and provided
that our board of directors may not elect external directors. Our amended and restated articles of association provide that the term of
a director appointed by our board of directors to fill any vacancy will be for the remaining term of office of the director(s)&nbsp;whose
office(s)&nbsp;have been vacated. Furthermore, under our amended and restated articles of association, our directors, other than external
directors, are divided into three classes with staggered three-year&nbsp;terms. Each class of directors consists, as nearly as possible,
of 1/3 of the total number of directors constituting the entire board of directors (other than the external directors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">External directors are elected for an initial term
of three&nbsp;years, may be elected for additional three-year&nbsp;terms, and may be removed from office pursuant to the terms of the
Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Dividend and Liquidation Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may declare a dividend to be paid to the holders
of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are determined
by our board of directors and do not require the approval of the shareholders of a company unless our articles of association provide
otherwise. Our amended and restated articles of association do not require shareholder approval of a dividend distribution and provide
that dividend distributions may be determined by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Companies Law, subject to certain
exceptions with the respect to the buyback by us of our ordinary shares, the distribution amount is limited to the greater of retained
earnings or earnings generated over the previous two&nbsp;years, according to our then last reviewed or audited financial statements (less
the amount of previously distributed dividends, if not reduced from the earnings), provided that the end of the period to which the financial
statements relate is not more than six&nbsp;months prior to the date of the distribution. If we do not meet such criteria, then the we
may distribute dividends only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors
and, if applicable, the court determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying
our existing and foreseeable obligations as they become due. In the event of our liquidation, after satisfaction of liabilities to creditors,
our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the
right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of
shares with preferential rights that may be authorized in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Exchange Controls</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are currently no Israeli currency control
restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of ordinary shares or interest or other payments
to non-residents&nbsp;of Israel, except for shareholders who are subjects of certain countries that are, or have been, in a state of war
with Israel at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Shareholder Meetings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under Israeli law, we are required to hold an annual
general meeting of our shareholders once every calendar year that must be held no later than 15&nbsp;months after the date of the previous
annual general meeting. All general meetings other than the annual meeting of shareholders are referred to in our amended and restated
articles of association as special meetings. Our board of directors may call special meetings whenever it sees fit, at such time and place,
within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene
a special general meeting upon the written request of (i)&nbsp;any two of our directors or one-quarter&nbsp;of the members of our board
of directors or (ii)&nbsp;one or more shareholders holding, in the aggregate, either (a)&nbsp;5% or more of our outstanding issued shares
and 1% or more of our outstanding voting power or (b)&nbsp;5% or more of our outstanding voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under Israeli law, one or more shareholders holding
at least 1% of the voting rights at the general meeting may request that the board of directors include a matter in the agenda of a general
meeting to be convened in the future, such as nominating a director candidate, provided that it is appropriate to discuss such a matter
at the general meeting. Our amended and restated articles of association contain procedural guidelines and disclosure items with respect
to the submission of shareholder proposals for shareholders meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the provisions of the Companies Law and
the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record
on a date to be decided by the board of directors, which may be between four and 40&nbsp;days prior to the date of the meeting. Furthermore,
the Companies Law requires that resolutions regarding, among other things, the following matters must be passed at a general meeting of
our shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">amendments to our amended and restated articles of association;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">appointment or termination of our auditors;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">election of directors, including external directors (unless
otherwise determined in our amended and restated articles of association);</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">approval of certain related party transactions;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">increases or reductions of our authorized share capital;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a merger; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the exercise of our board of directors&#8217; powers by a
general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our
proper management.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under our amended and restated articles of association, we are not required to give notice to our registered shareholders pursuant to
the Companies Law, unless otherwise required by law. The Companies Law requires that a notice of any annual general meeting or special
general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment
or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger,
or as otherwise required under applicable law, notice must be provided at least 35 days prior to the meeting. Under the Companies Law,
shareholders of a public company are not permitted to take action by written consent in lieu of a meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Quorum Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our amended and restated articles of
association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders
at a general meeting. Under our amended and restated articles of association, the quorum required for general meetings of shareholders
must consist of at least two shareholders present in person or by proxy (including by voting deed) holding 25% or more of our voting rights.
A meeting adjourned for lack of a quorum will generally be adjourned to the same&nbsp;day of the following week at the same time and place,
or to such other&nbsp;day, time or place as indicated by our board of directors if so specified in the notice of the meeting. At the reconvened
meeting, any number of shareholders present in person or by proxy shall constitute a lawful quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Vote Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated articles of association
provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by
our amended and restated articles of association. Our amended and restated articles of association provide that all resolutions of our
board of directors require a simple majority vote of the directors present and voting at such meeting, unless otherwise required by the
Companies Law or by our amended and restated articles of association. Pursuant to our amended and restated articles of association, in
the event the vote is tied, the chair of the board of directors will have a casting vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our amended and restated articles of
association, an amendment to our amended and restated articles of association regarding any change of the composition or election procedures
of our directors will require a special majority vote (66&#8532;%). In addition, any change to the rights and privileges of the holders
of any class of our shares requires a simple majority of the class so affected (or otherwise in accordance with the terms of such class),
in addition to the simple majority vote of all classes of shares voting together as a single class at a shareholder meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law, each of (i)&nbsp;the approval
of an extraordinary transaction with a controlling shareholder and (ii)&nbsp;the terms of employment or other engagement of the controlling
shareholder of the company or such controlling shareholder&#8217;s relative (even if not extraordinary) requires the approval of the compensation
committee, board of directors, and shareholders, subject to limited exceptions. Certain transactions with respect to remuneration of our
office holders and directors require approvals of the compensation committee, board of directors, and in the case of the chief executive
officer and directors, shareholders, subject to limited exceptions Another exception to the simple majority vote requirement is a resolution
for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section&nbsp;350
of the Companies Law, which requires the approval of holders of 75% of the voting rights represented at the meeting, in person or by proxy
and voting on the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Access to Corporate Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law, shareholders
are provided access to: minutes of our general meetings; our shareholders register and material shareholders register; our amended and
restated articles of association; our financial statements; and any document that we are required by law to file publicly with the Israeli
Companies&nbsp;Registrar (the &#8220;ISA&#8221;). In addition, shareholders may request to be provided with any document related to an action
or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request
if we believe it has not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or
patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Modification of Class&nbsp;Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law and our amended and restated
articles of association, the rights attached to any class of share, such as voting, liquidation and dividend rights, may be amended by
adoption of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in
accordance with the terms of such class of shares, in addition to the simple majority vote of all classes of shares voting together as
a single class at a shareholder meeting, as set forth in our amended and restated articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acquisitions Under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Full Tender Offer.&nbsp;</I>A
person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&#8217;s issued
and outstanding share capital is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the
purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of an Israeli public company and
who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender
offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of
that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company
or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer,
all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer
will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of
the company or of the applicable class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon a successful completion of such a full tender
offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may, within
six&nbsp;months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for
less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror
may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court
as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If (a)&nbsp;the shareholders who did not respond
or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the applicable class or the
shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance
of the tender offer or (b)&nbsp;the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share
capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings
to more than 90% of the company&#8217;s issued and outstanding share capital or of the applicable class from shareholders who accepted
the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Special Tender Offer.&nbsp;</I>The
Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as
a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. Similarly, the Companies
Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of more than 45% of the voting rights in the company. These requirements do not apply if, in general,
the acquisition (1)&nbsp;was made in a private placement that received shareholder approval, (2)&nbsp;was from a 25% or greater shareholder
of the company which resulted in the acquirer becoming a 25% or greater shareholder of the company, or (3)&nbsp;was from a 45% or greater
shareholder of the company which resulted in the acquirer becoming a 45% or greater shareholder of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A special tender offer must be extended to all
shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting power attached to
the company&#8217;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated
only if (i)&nbsp;at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by the offeror and
(ii)&nbsp;the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer&nbsp;(excluding the purchaser
and its controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal interest
in the acceptance of the tender offer or any other person acting on their behalf, including the relatives and entities under such person&#8217;s
control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with
the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company
and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or
such person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Merger.&nbsp;</I>The Companies
Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under
the Companies Law are met, by a majority vote of each party&#8217;s shares, and, in the case of the target company, a majority vote of
each class of its shares, voted on the proposed merger at a shareholders meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For purposes of the shareholder vote, unless a court
rules otherwise, the merger will not be deemed approved if a majority of the votes of shares represented at the shareholders meeting that
are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds (or hold,
as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, vote against
the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder or if the controlling shareholder
has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs all extraordinary
transactions with controlling shareholders. See&nbsp;&#8220;Management&nbsp;&#8212;&nbsp;Approval of Related Party Transactions under
Israeli Law&nbsp;&#8212;&nbsp;Fiduciary Duties of Directors and Officers&nbsp;&#8212;&nbsp;Disclosure of Personal Interests of an Office
Holder and Approval of Certain Transactions.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the transaction would have been approved by the
shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as
provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if
the court holds that the merger is fair and reasonable, taking into account the value to the parties to the merger and the consideration
offered to the shareholders of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the request of a creditor of either party to
the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result
of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions
to secure the rights of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, a merger may not be consummated unless
at least 50&nbsp;days have passed from the date on which a proposal for approval of the merger was filed by each party with the IRC and
at least 30&nbsp;days have passed from the date on which the merger was approved by the shareholders of each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli tax law treats some acquisitions, such as
share-for-share&nbsp;exchanges between an Israeli company and a foreign company, less favorably than U.S.&nbsp;tax laws. For example,
Israeli tax law may, under certain circumstances, subject a shareholder who exchanges his ordinary shares for shares in another corporation
to taxation prior to the sale of the shares received in such share-for-share&nbsp;swap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Anti-Takeover&nbsp;Measures Under Israeli Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Companies Law allows us to create and issue
shares having rights different from those attached to ordinary shares, including shares providing certain preferred rights with respect
to voting, distributions or other matters and shares having pre-emptive&nbsp;rights. As of the date of this prospectus, no preferred shares
were authorized under our amended and restated articles of association. In the future, if we do authorize, create and issue a specific
class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to
frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their
ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and restated
articles of association, which requires the prior approval of the holders of a majority of the voting power attaching to our issued and
outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate and the majority vote
required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law as described above in &#8220;&#8212;&nbsp;Voting
Rights.&#8221;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Borrowing Powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Companies Law and our amended and
restated articles of association, our board of directors may exercise all powers and take all actions that are not required under law
or under our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow
money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Changes in Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated articles of association
enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved
by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital,
such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both
our board of directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Establishment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We were incorporated under the laws of the State
of Israel on February&nbsp;13, 2017. We are registered with the IRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain legal matters with respect to Israeli law
and with respect to the validity of the offered securities under Israeli law will be passed upon for us by Goldfarb Gross Seligman&nbsp;&amp;
Co. Certain legal matters with respect to U.S.&nbsp;law will be passed upon for us by Greenberg Traurig, P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>EXPERTS</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial statements of the Company
as of December&nbsp;31, 2023 and 2022 and for each of the&nbsp;years in the three-year&nbsp;period ended December&nbsp;31, 2023 have
been incorporated by reference herein in reliance upon the report of Somekh Chaikin, a member firm of KPMG International, independent
registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and
auditing. The audit report covering the December&nbsp;31, 2023 consolidated financial statements contains an explanatory paragraph that
states that the Company&#8217;s recurring losses and its expectation to incur significant additional losses raise substantial doubt about
the entity&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that
might result from the outcome of that uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>EXPENSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Set forth below is an itemization
of the total expenses, excluding placement agent discounts, expected to be incurred in connection with the offer and sale of the securities
offered by us. With the exception of the SEC registration fee, all amounts are estimates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">SEC registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,890.79</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printer fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Miscellaneous</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">22,609.21</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">85,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_016"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus is part of the registration statement
on Form&nbsp;F-1&nbsp;we have filed with the SEC under the Securities Act, with respect to the securities offered by this prospectus.
However, as is permitted by the rules and regulations of the SEC, this prospectus, which constitutes part of the registration statement,
omits certain non-material&nbsp;information, exhibits, schedules and undertakings set forth in the registration statement. For further
information about us, and the securities offered by this prospectus, please refer to the registration statement and the exhibits and
schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated
by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities
in any state where the offer is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to the reporting requirements of
the Exchange&nbsp;Act that are applicable to a foreign private issuer. In accordance with the Exchange&nbsp;Act, we file reports, including
annual reports on Form&nbsp;20-F&nbsp;by April&nbsp;30 of each year. We also furnish to the SEC under cover of Form&nbsp;6-K&nbsp;material
information required to be made public in Israel, filed with and made public by any stock exchange or distributed by us to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The SEC maintains an internet site that contains
reports, proxy and information statements, and other information regarding issuers, such as us, that file electronically with the SEC
(<I>http://www.sec.gov</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a foreign private issuer, we are exempt from
the rules under the Exchange&nbsp;Act prescribing the furnishing and content of proxy statements to shareholders and our officers, directors
and principal shareholders are exempt from the &#8220;short-swing&nbsp;profits&#8221; reporting and liability provisions contained in
Section&nbsp;16 of the Exchange&nbsp;Act and related Exchange&nbsp;Act rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_017"></A>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We file annual and special reports and other information
with the SEC (File Number&nbsp;001-41084). These filings contain important information which does not appear in this prospectus. The SEC
allows us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information
to you by referring you to other documents which we have filed with the SEC.&nbsp;We are incorporating by reference in this prospectus
the documents listed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our Annual Report on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024030439/ea0202964-20f_neuro.htm">Form 20-F</A>&nbsp;for the fiscal year
ended on December&nbsp;31, 2023, filed with the SEC on April&nbsp;4, 2024;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our Reports on Form 6-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024032576/ea0203662-6k_neurosense.htm">April 12, 2024</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024040296/ea0205419-6k_neuro.htm">May 7, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024046254/ea0206776-6k_neurosense.htm">May 23, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024046796/ea0206851-6k_neurose.htm">May 28, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024053407/ea0207963-6k_neurose.htm">June 17, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024054830/ea0208261-6k_neurosense.htm">June 21, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024055014/ea0208354-6k_neurosense.htm">June 24, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024056329/ea0208577-6k_neurosense.htm">June 27, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024057567/ea0208449-6k_neurosense.htm">July 1, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024058810/ea0208944-6k_neurosense.htm">July 3, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024059941/ea0209065-6k_neurosense.htm">July 9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000101376224003567/ea0210415-6k_neurosense.htm">August 1, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024065940/ea0210783-6k_neurosense.htm">August 7, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024070239/ea0211530-6k_neurosense.htm">August 16, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024072385/ea0212366-6k_neurosense.htm">August 26, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024073108/ea0212491-6k_neuro.htm">August 28, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024074611/ea0212798-6k_neuro.htm">August 30, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024076685/ea0213897-6k_neuro.htm">September 9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024081228/ea0215474-6k_neurosense.htm">September 24, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024083414/ea0216145-6k_neurosense.htm">September 30, 2024</A> <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024086415/ea0217150-6k_neurosense.htm">October 9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024087526/ea0217618-6k_neurosense.htm">October 15, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024090144/ea0218521-6k_neurosense.htm">October 24, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024090982/ea0218396-6k_neurosense.htm">October 28, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024092005/ea0219160-6k_neurosense.htm">October 30, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024092946/ea0219483-6k_neurosense.htm">October 31, 2024</A>
and <A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390024096273/ea0220815-6k_neurosense.htm">November 12, 2024</A> (in each case, to the extent expressly incorporated by reference into our effective registration statements filed
by us under the Securities Act); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the description of the ordinary shares contained under the
heading &#8220;Item 1. Description of Registrant&#8217;s Securities to be Registered&#8221; in our registration statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1875091/000121390021060442/ea150948-8a12b_neurosense.htm">Form 8-A</A>, as filed with the SEC on November&nbsp;18, 2021, including any subsequent amendment or any report filed for the purpose of updating
such description.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information relating to us contained in this
prospectus does not purport to be comprehensive and should be read together with the information contained in the documents incorporated
or deemed to be incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As you read the above documents, you may find inconsistencies
in information from one document to another. If you find inconsistencies between the documents and this prospectus, you should rely on
the statements made in the most recent document. All information appearing in this prospectus is qualified in its entirety by the information
and financial statements, including the notes thereto, contained in the documents incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will provide each
person, including any beneficial owner to whom a prospectus is delivered, without charge, upon a written or oral request, a copy of
any of the documents incorporated by reference in this prospectus, other than exhibits to such documents which are not specifically
incorporated by reference into such documents. Please direct your written or telephone requests to NeuroSense Therapeutics Ltd., 11
HaMenofim Street, Building B, Herzliya, 4672562, Israel, Attn: Or Eisenberg, telephone number +972587531153. You may also obtain
information about us by visiting our website at&nbsp;<I>www.neurosense-tx.com</I>. Information contained in our website is not part
of this prospectus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>ENFORCEMENT OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated under the laws of the State
of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this prospectus, substantially
all of whom reside outside the U.S., may be difficult to obtain within the U.S. Furthermore, because substantially all of our assets and
substantially all of our directors and officers are located outside the U.S., any judgment obtained in the U.S. against us or any of our
directors and officers may not be collectible within the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have irrevocably appointed Cogency Global Inc.
as our agent to receive service of process in any action against us in any U.S.&nbsp;federal or state court arising out of this offering
or any purchase or sale of securities in connection with this offering. The address of our agent is 122 East 42<SUP>nd</SUP>&nbsp;Street,
18<SUP>th</SUP>&nbsp;Floor, New&nbsp;York, NY&nbsp;10168.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have been informed by our legal counsel in Israel,
Goldfarb Gross Seligman&nbsp;&amp; Co., that it may be difficult to initiate an action with respect to U.S.&nbsp;securities law in Israel.
Israeli courts may refuse to hear a claim based on an alleged violation of U.S.&nbsp;securities laws reasoning that Israel is not the
most appropriate forum to hear such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli
law and not U.S.&nbsp;law is applicable to the claim. If U.S.&nbsp;law is found to be applicable, the content of applicable U.S.&nbsp;law
must be proved as a fact by expert witnesses which can be a time-consuming&nbsp;and costly process. Certain matters of procedure may also
be governed by Israeli law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to certain time limitations and legal procedures,
Israeli courts may enforce a U.S.&nbsp;judgment in a civil matter which, subject to certain exceptions, is non-appealable, including judgments
based upon the civil liability provisions of the Securities Act and the Exchange&nbsp;Act and including a monetary or compensatory judgment
in a non-civil&nbsp;matter, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the judgment was rendered by a court which was, according
to the laws of the state of the court, competent to render the judgment;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the obligation imposed by the judgment is enforceable according
to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the judgment is executory in the state in which it was given.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Even if these conditions are met, an Israeli court
will not declare a foreign civil judgment enforceable if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the judgment was given in a state whose laws do not provide
for the enforcement of judgments of Israeli courts (subject to exceptional cases);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the enforcement of the judgment is likely to prejudice the
sovereignty or security of the State of Israel;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the judgment was obtained by fraud;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the opportunity given to the defendant to bring its arguments
and evidence before the court was not reasonable in the opinion of the Israeli court;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the judgment was rendered by a court not competent to render
it according to the laws of private international law as they apply in Israel;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the judgment is contradictory to another judgment that was
given in the same matter between the same parties and that is still valid; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify">at the time the action was brought in the foreign court, a lawsuit
in the same matter and between the same parties was pending before a court or tribunal in Israel.</TD>
</TR></TABLE>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">If a foreign judgment is enforced by an Israeli
court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli&nbsp;currency and transferred out
of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli&nbsp;currency is for the Israeli
court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment,
but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated
in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli
regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Up to 10,000,000 Ordinary
Shares</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 51pt; width: 205.5pt"></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: normal 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NeuroSense Therapeutics Ltd.</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>November 22, 2024</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ 1(# 2(  A$! Q$!_\0
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M?3(XI+X;F=!26%==-\R3*OAG37\16=Q?:I=7,K,Y2/$I4+ZD 5F:7KE_H?B
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M %JR34Q86P?4[:=A$N9@/]8<#YOQZT5S4'PLM([>)'U:^W*@!V-A<X[#L**
M._HHHH **** "L_6;*#4-+N+>X3<A4GW!'0CWHHIIV=T3)75F6[<!;:(#H$
M_2I:**&-;!1112&%%%% !1110 4444 %%%% !1110!F:UH5EX@MEMK_SFA4[
MMD<K(&/OCK5JQLX]/M4MHGE=$Z&60NWYGFBB@"S1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDR*6@ HHHH
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MQ+XPUW<<3/<:EJ4HZ><ZKN;\JU^K5/9^U<?(P^M4O:<BD>W_ /?-&X^B_G7
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M19QL=?E9/[K4Z<LJ^8J[G7MZU5FD6&ZBD7Y/-^5EV_>JB?A-*DI:*DH^0IO
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M/ K&66/&QVX^9EVKM],4D?A'1(VA:/2K%3!<M>1%;9/DG?.^5>/OMN/S5O\
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M-T:1_P!"QJ'_ '_B_P :?_PW)I/_ $+&H?\ ?Z/_ !KV/]6\V_Y\_E_F?/\
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M8C/,OPM1T:]3EDO7_(^B/Q%&?<5\]?\ #86F?]"Y??\ ?Z+_ !I__#7VF?\
M0O7W_?V+_&M_[(QO_/M_@8?ZR97_ ,_OS_R/H/(]J,CVKY]_X:\TW_H7K[_O
MZE+_ ,-<Z;_T +S_ +^I4?V5CO\ GV3_ *R95_S^_/\ R/H%MJXYQ2MV(YKY
M[_X:VT['.@7A/_71*ZWX=_'K2?'VJ2:<8)=.N]N^!+AE/FC_ &>>OM653 8J
MC'FG Z:.>Y?B*D:=.I[TCU=F"^U-^][UP'Q(^*#?#B.&>70[J^LI/E-U!(H5
M&_NL#TKA/^&L--_Z 5Y_W]2LJ6$KUH\T(W-<3G&!PE3V=>?++YGO?Y4?E7@_
M_#5VG_\ 0!O/^_J4?\-7:?\ ] &\_P"_J5M]0Q/\AR_ZPY;_ ,_?S_R/>./[
MPHRM>%?\-4Z?_P! *\_[^I3_ /AJ?3_^@%>_]]I4_4<1_*/_ %ARS_G[^9[B
MT@7&>M*OS>X->&?\-1:<W70[P_\  E_QK>\%_'[2?%NLIILEM-ILLG^I:X*A
M96_NCWJ982O"/-*)M3SO+ZTXTX5-3U7GMTI-A;D\UR'C[QS)X$TU;\Z5/J%J
MO^N>W91Y(]6_V:\\_P"&I].[Z%>'_@:UE##U:BO")KB<VP6#GR5I\K^9[G^5
M'Y5X7_PU1I__ $ ;W_OM*3_AJK3_ /H W?\ W]2K^JUOY3C_ -8<M_Y^_G_D
M>[T5X+_PU9I__0!N_P#OZE)_PU?IO_0"N_\ OZE+ZO5["_UCRS_G[^?^1[RV
M,CUI<^HP*\"_X:OT[_H!7?\ W\2M/PK^TOHOB/6H-/NK*XTM9SA)YY%*;_[C
M?W:GV$^QI3X@RVM*,(54>U_=]J8WS>]<MX\\73>"=$?4HM*GU6./F5+=U5D7
MNW/6O*?^&N--_P"@!>?]_4J8TY2^$WQ6;X+ RY,14Y7\_P#(^@?RI.?]FOG[
M_AKK3?\ H 7G_?U*;_PUYIW_ $+][_W]2CV<C@_UFRK_ )_?G_D?0>X>OZ4N
MX>OZ5\]_\-@:;_T+M]_W\2F?\-AZ;_T+M]_W]C_QI>SD'^M&4_\ /[\'_D?0
MV['4XI&Z_=R:^>?^&P--/7P[?%O^ND?^-=G\+_CQH_Q,O+FP2.33-0A^9;:X
M*Y=?[Z^HI<K-L/Q!EF)J1HTJJ<I'JF=O6DW!_?ZBO+/BE\9G^%]W MWH-Y>6
M<W$=];LNS?\ W&_NFN'_ .&RM,_Z%R^SZ^;'_C2#$\0Y=@ZKHXBIRR7D_P#(
M^C-WN?\ OFDW'U_2OG+_ (;+TW_H7+[_ +^Q_P"-)_PV9IG_ $+E[_W^C_QI
M:''_ *V9-_S^_/\ R/H[GU'Y4G/K7SC_ ,-I:7_T+5]_W^C_ ,:9_P -K:7_
M -"U?_\ ?Z+_ !I<R#_6K)O^@C\_\CZ6W4;J^:/^&U-)_P"A:U#_ +_1?XTG
M_#:NC_\ 0M7_ /W^B_QJ+Q[A_K;DW_00OQ_R/IC\*/PKYF_X;6TG_H6K_P#[
M_1?XTG_#;&D_]"U?_P#?Z+_&HYX"_P!;LD_Z"(_C_D?3 P>^:6OF-?VV-,:1
M1_PCU\ >WF1?XU]*VLHGB20<!UZ5I&49?">OE^;8/-.;ZI/FY2U1113/:"BB
MB@ HHHH **** "BBB@#\@?C]_P EU^(?_8<O/_1KUP3?<K] ?'7[ =AX[\;>
M(/$<WC.\LI=7OI;UK9+%'6+<^[;NWUC_ /#M?3?^A]OO_!<G_P 70!X\W@7X
M9:E8:.UU+#;7=U8V=KOL=3BMTMY?[*>X>XE3YMS>>FQON_,]:K>$_ 'A_P '
MRVECJ&FPHT%U*NN/?6MU<7BMIJ?/Y6S=$GFM*OE?>W)_>KTO_AVGI?\ T/E]
M_P""R+_XNC_AVGI?_0^7W_@LB_\ BZ /)+?X,_#RYO\ Q;%<WUM8:99VK?V5
M<+XG@N);S;%*R76S[JJ^R)=GWE=ZO7GA+X>:U<:A;02:?H^E74MA=6=I;ZM;
M_P"GM_9LK[/-=-UKON$2)M_\7WOOI7IG_#M'2O\ H?+S_P %<7_Q=+_P[3TO
M_H?+[_P61?\ Q= 'B^J_#3X86=K<107TCW=Q%>;9DUV)DL+B+3XKA(ON?O\
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MYEA^M:1K+(L?/X,+&/S1\W+]U-U6K-YTNK=K-I$NUE7R/)^_N_@V?[5?0O\
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M/[L?_?NC_A-M8_NQ_P#?NO+/M3T:BO.?^$VUC^['_P!^Z/\ A-M8_NQ_]^Z
M/0OO?C69K&MV^AVYEN6P@X5>[&N0_P"$TU?^['_W[KRSX^:]J6I>%XD9MGVB
M=;>78NW]U]^M(QYY<IYV.Q3P>&GB(QYN5';K^T!X=N-0$"WMF[AMF?,?_P!"
MV[:],T;6+;6+436S9_O+W6OCU? =IX-M6U;Q!>V\^DHBM;_89=[:@_\ =C_N
MK_>;^']:]!^ _BZ]F\-SSPIL2&ZE@B5OWNR+Y6V?\ KT*N#E&C[6)\QE&>5\
M77^KXF"4I:Z?J?2]%><_\)MK']V/_OW1_P )MK']V/\ []UY9]P>C45YS_PF
MVL?W8_\ OW1_PFVL?W8_^_= 'H=4=2U:#2[5IIVP!T7UKBO^$SU?^['_ -^S
M7GWQJ\2:I<>";QPS),VR(^4NW:K-AJN,>9\IR8NO]6H3K?RJYU,WQ^\/VVI-
M;?;[3<C;' D9A_WVJ;?UKT30?$-GX@M_.MF&2,E<\U\>Z5\/;70;&/6=9O[<
MZ!Y23+):2[GG;G]Q&G][@[O[M=K\ ?%US<1ZV;.)HK2"Y_T:)V\WRE;_ )9;
MOXJ]*6!E["59?9/D,JS[$8NNJ.*@ES;6/J>BO.?^$VUC^['_ -^Z/^$VUC^[
M'_W[KRC[H]&HKSG_ (3;6/[L?_?NC_A-M8_NQ_\ ?N@#T3WJGJ6H0:;:O/<-
ML1?UKA_^$UU?^['_ -^ZX[XI:[J>H>$[E3/%I[OMB6X9'5(E=U5W?_@-!S8F
MLZ%"=5?9-J\_: \/V>H?8VNK4R(VQU$C,%_X$J[:[WP]XHM/$%OYMNXSMW[0
MV[Y?45\E0_#,>#=,GN=8M7U"=]T=C8Z:Q;SF;[L[,OW8^/E_O5TWP"UK5]/F
MU:UECGA:S:)HHKB)EV^:G]S_ ,>KU98+_9W670^+RW/L3B,4L/B(6YOP]3ZO
MHKSG_A-=8_NQ_P#?NC_A-M8_NQ_]^Z\H^]/1J*\Y_P"$VUC^['_W[H_X3;6/
M[L?_ '[H ]&JO>7D5C;O/,VR->IK@?\ A-M8_NQ_]^ZHZMX@OM6MTBN=J(K;
M_E7;0!NW'Q";?^XL_P!WZRM6UH?BBVUO,6TPW"_\LG[UYI4MG<26-U%-!_K5
M;<M 'L=%><_\)MK']V/_ +]T?\)MK']V/_OW0!Z-17G/_";:Q_=C_P"_='_"
M;:Q_=C_[]T >C57NKJ*SMWFF?9&OWFK@?^$VUC^['_W[JCJGB+4-4M_(N=J1
M;MWRKMH W;CXB?O/]&L]\7]^5L5KZ'XLMM6E\EE^SS_PH?XJ\WIUM,T-Q%+%
M]Y65UH ]FJ%MVQMOS-_#NJ:H9'\M68*S;?X5H R?"]YK-UH-G)X@L[6PUED_
MTFWL9VEA5_1'95W?E7G7_"3^.[76%']FW-W8QW=Q<#9:[?/@:*7[/!_L[7B^
M9O\ :B_OUZ-X4UYO%'A^RU*73;[1WN$W&QU*+RIXO]EEKA[CXQ);V-V[V;)/
M%N42*5>'=FX\O^-6_P"7=MU $UQXL\775M)%:Z0L=PUM++%<;6V,WS[?E_A9
M=J?*WWMU5=/\9^*;=YVFTMKF!5@E:6:"6+=N6W1]GR_)R\K?Q?<:G1_&-+07
M$FHVJPK%%=2K;Q'?--Y4\J?+[[(F;;_X]6K:_$6.\NXK*;3Y6GNKF:.-;<>;
M^Z29(][_ /?:EE[+0!3TCQ[JM]H-UJBZ=!=W$$MN_P#9UJKFX6"1$^;;_>^9
MO^ I57_A*O&-]>6$KZ2VEJ'6*Y3RWE7Y;B)96^[]W_6[6_N?-3+SXC6GAG5M
M1T_3=*MXK&-]D$L2M$DTZ2HMPGW=OR+(/^^'_NUU7_"32IXJN=*N;9K9?+::
MSFSN6Y5%3?\ -_ RL^-K=OFH P[/5_%4/A*[5H&_M.VM;::*=[5G=MSMO1D_
MB957^'^]5>#Q1XJTO?"-*?4$DN+AHKJ:*1!&OVB95W?[.U8MO^RU1Z?\3-38
M6%_J.EK'I5UI_P!M\V+Y7V_Z/GY6YVJTK?[W%:LOQ>TBV:=YHIUMXFPUSMW1
M-\F]=O\ OK]S^]0 SQ)J7BJWEU>2SCF1;?15N(UA59?]*_>_(O[K][]U./E_
M\>K-U+Q%XMAGD6RM[J_M+.Z:\,S6B*UU9ILW1?[^YI=NQ=W[I?[]=!-\1((?
M"<VOG3[U(8FVM%)'M9E_OJ?[O3YONU%XF\>?V6M]'8QJ]Q8W%FD[R?<_?RH/
ME_O?*WWJ (M>\9:[;:]_9VG:-)<V[/$GVN2"4HFYXMS_ "_>7;*W]W_5/4&D
M^)?$>N:YI,=WI\NE0QSLL\7D2?OU\F7Y]_W57?L^4_-51?C+;_V/8W,EM)"L
MI57FV;T;;Y7F[%5MW_+5=M6?%GQ4BT71"]M$OVZ2U$\>X^:D>Y'=/-V_WEB:
M@#*7Q1XOAT#3KXV]]=7L-Y)+?6B6GSRVZ[D\I?W2[6^9&_B^Y]ZG:3XB\:VZ
MZ4M];3S_ &&Y>+5W2SV_:5>X>)3%_LJNV7Y?X:]=HH **** "BBB@ HHHH *
M*** "BBB@ K,;3+.34%OY+6%[R.-HDN#&OF(C'YEW?W?E'Y5IT4 <JWPW\*/
M-%*_AG1VDA/[IVL8BT?S%OE^7CYF;IZUI:'X9TCPO;O#I&EV>EPR-N>.RMUA
M5F]2%%;%% !1110 4E+10!#Z,>#7"?$3X<V_C*Q=2N)3_=.U@W]]?]JN[D"]
MSBG*O'/(JXRE3ES1.>K2C6A*E4C[K/DJ;]F/6=2U"*.YU.Y>R4;500?.J?W-
MS/M6OHCX>^![7P+HL5G;QJ@C78JIT5?2NNX;BFKCG%=>(QU?$PC"<O=1YV#R
MG"9?.4\/&TI$E+117">R%%%% $94;>M<;X^\"V_C#37B==[;=K+G;N_^RKL_
MO4C ;13C+E9E4IQJQY)_"?)NH?LR:S?7R0MJ=Q]A1OE7R/G3_=^?;7O7PW^'
M]IX!T>*RMHM@C7:JYWD=-Q9N[-7;C/<TNT<CI7;B,=7Q,(TIOW8GEX/*<'@9
MRJT(6E(DHHHKA/9"BBB@!O85S/C3PC;^*=+>"1%?*[2K?Q+_ ':Z?C'M2<4&
M=2G&I'EEL?)VL?LSZS>7GD1:G<I8HV]8G@WNG^Y\^VO:OA3\+;7X>Z6EO"IW
M+SEGW,S-]YW_ -JO1!DMG.11PH.*[ZN.KUJ?LIR]T\C"91@\'5=:C"TB6BBB
MN ]L**** &XKGO%GA:+Q-IDEM(J/E678WW64_P )KH5;-#4$RBIKED?+6K?L
M^^)(]0"V&NW]E;'8 JJS.JK]SYU?^&O7?AG\,QX+M=T\UQ<73$%YKN7S)96V
M[-[-G^[\JK_"*]#^9>,DTH7;U.?:NZKC:M6G[.3T/)PV583"U95:4?>)J***
MX3V HHHH *RO$&BKK5B8=VR5?FC?T:M6B@#RFX\.:E;3;6L9'_VD7>E;_A?P
MG/#=)=WR[/*^:.+T:NWHH **** "BBB@ K,US1TUK3W@9MC_ 'D?^ZU:=% '
ME-QX9U.SDVM9R/\ [<7S)6QX=\(3M=)<WD7DQQ/N6)OO-7?44 %%%% !7!3>
M./"WG0Q")9+>=)Y3=K9M]G7RG5'W/M_O2[?^^J[VN5F^'V@W,ER\MEO>ZW>>
M?-?=+OV;MWS?],D_[XH QM:\9>$[2412VMO>I)=/#>.MKO6#;YNYY?E_O1/7
M3Z>NE:LHN[2"WN%2=RDRQ*1YBG8S*?7Y=N[_ &:H1> =&LY)I+2U\BX=VE:9
MI'??*V_YG7=\Y_>O][^]6QH.BVWAO1+#2[1=EK9PI;QC_95<"@!9-)L;J/RY
MK.&:/<S;9$5EW-]ZG6^CV-E(TEO96\+LNTO#&J_+6A10!1_L^W:-(_(C\M$V
M*NWHO'R_^.K4<>@Z;#*)8["U216W;EA4-N]<UI44 8MYX:L+S3_L7D+#9YRT
M%O\ NDDZ_*VW^&KDNFV=Q(LLUI#-*J[0TD:LVVKU% &>NEVJ,NVSA3;]W]VO
MR_YVK4?_  CNF+M_XEUI\J[5_<+6I10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 )2T44 %%)D4M !1110 4444 %%)D4M !112
M4 +1110 4444 %%%% !112;A0 M%%% !1110 4444 %%%)0 M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 445\S?&?5/%U[\2O[>T;1-4O-
M*\#M9S?Z/*\7VII7W7:I%M_?_P"C[%_V&W4 ?3-%?+NEZSK^B>(++3K?4==T
M.UO_ !5J=U<M_9;W%O+9_:_E3YXG9&EWHJ_,JJF]JP_"^N?$_P "_#K3;32H
MM3O VA6]S]GN-/(?3G^VB*7;^Z9G;RF9MK[V^3=M_@H ^N=Z[MNY=_WMM2U\
MK1:QX[DU+3=325IM:N+2RL&UNTT9F86\NKLCX\R)/F\K:[?*J_+NVU>NO&/Q
M9T'2[V>TFO\ Q)>_9M;B@M[G24BVO:W2);S?*B;G>)V;;]U]GR+0!]-T5\Z>
M"]:^(OBS5O#EA<^)9[;39UO[B:[BTK#2K&]OY44KRV\6UOGE^ZB[E7_@5:/@
MVWUOX>_$S1_ ]A=ZEJ?A.STT01+%;_)!(L6YGNI7B^;>WW?*E^7[NR@#WJBB
MDH 8W"\BN/\ ''Q L? ^FRW-S(L01=S,W\(_]F;VKKR>-IYKYH_::M9[J^L3
M)N^R+<_O=O\ N)L_]GK2G'FERGD9KBIX+!SKTHWDBY8_M/17=]AX;F&VW?ZV
M6)0G_?/WZ]N\*^)K;Q-8K/"ZDLN[*G*M_M+[5\DZA=>%OA[:F_TZ]@\1W]T/
M]!MYH_DM%_B:9?\ GI_"J_\  J[_ /9_DU:Y\#PRV_VC<TLOE>5_SRW_ /H.
M_=7J5L%[/#^W/F,DS?%8C$?5\4U)M7TZ?=H?3-%>;^7XE_ZB'_?5'E^)?^HA
M_P!]5XY]\>D45YOY?B7_ *B'_?5'E^)?^HA_WU0!Z%MW<]-U<WXR\96G@[37
MNKF58U1=VY_NJO\ >-8'E^)?^G__ +ZKRWX_6>JW/AFW2[\[_CZ5I?-_N_/L
M_P#'JTC'GERGF9EB9X/"SKTX\TDBQ;?M017&H;4@N_LN['G-$FW_ +Y^]7M?
MA'Q9:^*;%+BW=6.W>"OW77^\OM7RC+_PBG@6S76+>]CUZ:5?^)?I\OR>6W\3
M7*_[+?=7^*NX_9_N-7U+PO<7,/F;I;R5XOL_R?)\F_;_ +.ZO4JX+DH>V/D<
MCS?%8C$?5\5)2<DWIT_X<^GJ*\W\OQ+_ -1#_OJCR_$O_40_[ZKQS]!/2**\
MW\OQ+_U$/^^J/+\2_P#40_[ZH ]$S6%XF\1VWAFPDNIRJA59LNVU?]YO:N7V
M>)/^G_\ [ZKSSXW6^K3^![N*X-QN9TW^;_SRW?/5QCSRY3AQU:>&H3JPCS65
MR%OVHH9M0"017,UON_UR1*B?]\M\U>P^!_&]GXPLTE@97.W>&4_>KY:D;PKX
M"M3J=E=KK]Q.N-/LIT_X]F_B:X7_ &6^ZO\ %V]:Z+]G.ZU2^L=9EM_,PUS^
MX\K^]L^?;_XY7LU,!RX66(_E/ALFSO%XC%QP^):DY7VZ'UI17F_E^)?^HA_W
MU1Y?B7_J(?\ ?5>&?HYZ117F_E^)?^HA_P!]4>7XE_ZB'_?5 'HB@UC^(O$$
M'AVQ:YF90O8,VW-<EY?B7_I__P"^JX;XP6NM77@74(93<>:R?\M/[F]-U:1C
MSRY3CQ=:6'H3JPCS<J;*-S^U!!-J316D5U/!G'G11JJ'_=W?-7K7@/Q[9^-K
M%7B=7;^%U_B_^);VKY.OG\$:;'=?9FU?I%Y&[;G=_P M=W_ /NUW/P/F6\UC
MQ'+X=^VOI'G1+9O-_K-^SYZ]>I@.6@ZO8^"R;.L9B,8J.(DI<W;H?5U%>;^7
MXE_ZB'_?5'E^)?\ J(?]]5XA^DGI%%>;^7XE_P"HA_WU1Y?B7_J(?]]4 >D5
MG:QJD>CV;7$GS?PJG]YJXCR_$O\ U$/^^JHZHNJK$G]H?:=F[Y?-H NW'C35
M)I-RR+"G]U5K=\,^,&U"X6TO%5+AONLO\5<'4MMYGVB+R-WVC?\ )L^_NH ]
MCHKS?R_$O_40_P"^J/+\2_\ 40_[ZH ](HKS?R_$O_40_P"^J/+\2_\ 40_[
MZH ](JCJVI1:59O<S?<7^'UKA?+\2_\ 40_[ZJCJBZNL*_VA]I\K=\OG?<W4
M 7;GQMJ4TFZ-EMT_N*N:U_#OC1KR9;:]V[V^594[UQ-.AW^;%M^]N7;0![-1
M14,D?F*RAF7=_$M $U-W?-BL7PMH]QX=T&TTZZU2\UR>W3:VH7VSSIO]I]BJ
MN?PKCSX9\3Q:2ME!/$LHEE>2\6X:.6ZWA]CM\GRLK.K;?]F@#TRJXN(O,6+S
M%\UEW*N?FV^M>8S>$O&]O"\R^('FND5G^6=MK-]J5N$V;?\ 4;DV_P![_OJJ
M>F^$/&EQ#I^HR7WV6Y^S(&@N)V:=5)@>6+S=OR[S$W^[F@#UUI%5@NY=S?=J
M6O+E\%>([>^^TV]ZLK%UEDFN)_WLO^CQ1.OW/W3?NF^=/[]7-%\,^++/6+>Y
MNM9\ZW6=6:V>=GVP;)=R?=^9MSQ?-_L4 =Y-=0VZ;I95B3=MW,VWYJ)KJ&';
MYDD:;FVKN;^+TKSZW\)^(;S5K"?5+];BWM;N*XVB=OF9?/W2K\ORY\V)?+Z?
M)5>\^&-Q>ZD]]+,HF76?MJ%9'7;!O5OO?WOD_P" T >I45Y-'X>^("QQ"75K
M=WBM4B_=73JLLJ^5\[_)_L2[MFW[];VDZ5XCM;/6?M=RNI7DRL+:%[EHH/ON
MR_=7=%\K*O\ P"@#NZ*Q_#=G>6.@6%MJ%PUS>10*DTKMN9V[MNK8H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &=JYCQGX)M/&5
MB\4ZJ=Z[&W?=9:Z?K2MBA/EV,YPC4CRRV/G&/]E'3YM0\V9[F6WW9\IKKY/_
M $#=7MGA?PU!X9L4M;>-(T150!5VJJ_W5]JW^*#[#-=57%U<0HPJ2ORG%A<O
MPN#<I4()<Q+1117*>B%%%% #=OI7/>+/"=MXFL7@F1267;\R_*R_W6]JZ%6S
M0W-!$HJ:Y9;'SC+^RGI]UJ'FR/<_9]V?*^U?)_Z!NKVCPEX1M?"6FI9VL,<:
M(NT+$NU57^ZOM72'\Z0Y[ &NJKBJV(C&%25['!A<MPN#E*=""3D2T445RGI!
M1110 AK'\0^'X/$5@UO,,-_"^VMFD/:@35U9GSGJ7[*VGW^I>9NNH[=FSY,5
MRNS_ ,>3=7KO@7P'8^!]+BM;.*.)47:JQ_=7Z5U7TYHX;C@UU5,97K05*<KQ
M/-P^6X7"3E5HP492)J***Y3TPHHHH 0UF:YH<.MV1AD&UOX7'5:TQ10&^C/G
MW5OV8M+U74&F\B6-';++;W.Q/^^:].\#^ ;'P7I\=O;6\<"HNQ4CX5?_ ++_
M &J[#GZT<-P<&NJ>+K5(>SG*\3SJ&7X7#3E5HTTI2):***Y3T0HHHH *SM6T
MN'5[-[:;[K?=;^ZU:-% 'G-QX%U*&3;%Y<R?W]VRMWPSX/\ [*D^TW+*]Q_"
MJ?=6NIHH **** "BBB@ JCJ6FPZK9O;3KE&_\=J]10!YS<^!=2ADVP>7<)_>
MW;*UO#?@YK&X6YO75Y5^Y$O\-=A10 4444 %>8KJGCJ9))?L-O;R*9V$+1;Q
MO17V)N^7Y6^3YO\ ::O3J* /,4U7QMY-O_Q+4=I'=MGE[1M^T;-C/O\ E_<?
MO-W\3?\ ?%9/A_\ X3VR46H6X2-I;<F6^C\]]K-$LOS[_P"%-[?[U>R44 >6
M:;K?C[4(XVNM/M=/D)@5OD=FPS1;W3^'^*7Y6;^!:JW6I>+;;PWXHO-5EN+=
MV@M6B\J+:MO'A%N'7_:QO?\ V:]=HH \PCD\1V-^DL:W<NBQ->&-+/9([1;4
M,&W=][^+;6KJ.I>);?3]$$-M]IU.2!Y+Q3%BVW)$?DW?>5FE*;?^!5VD<:PJ
MJ*JHB_*JK4U 'G,.M>*5^QE;.:?,\KLLL*1>; L7W6_NR^:=J_P[%W-6=X,U
M[6-7US1FU+=!JN_48+RVC&R'[/'-MC;;O;[K;55_XOGKU>H_+7?OVKN_O4 2
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 44FX49% "T444 %%%% !1110 44F12T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3IOC1!;AO*TB2=@D\C>5.I5/*2=F5_[K_P"C_=_VUH 2'5O',+2W#60DEF2
M)#)!^ZM_EEW-\K;OF98MR_P[_P#9J;4K[QM<75DNQ;>+[4K3O:6V[;&L[IM^
M9_F5TVM4MY\78]/DO8GT>ZDELHI99U65-GR+O^1FQN_VO[E:'A_QY-K?B==.
M:SCM(TBE\SS)PS>:HA;"<?,-LXH YC3]2\:7EQH-E-IM]:6L;VS7,S;M^Y=G
MF[G+?,C;G_VOEKV*BB@ HHHH **** "BBB@ HHHH **** "BBB@ JA_9]O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445$TBJRJS+\WW: ):
M*** "BBH&N(XVVLZKQN^9J )Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>;\G^U'_ -\5Z+10!Q>C>'M8M?%DU_=W;W%IY,D,2F;[J^9N3<NWKBNTHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\]^+VJ:EI/@NZFT2[:VUW>OV&-3\UQ+DMY2KL;?NQ]W]5KT*B@"
.../YE5MNS_9J2BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPY_:FU_PL(K37D;7M/7"B5FQ<H/]X\/_ ,"Y/K7TKX&^,_A;X@(BZ;J4:WC
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MR/@?G:IP<'H>U)M%?47P=^'.E?%3X$_V9?J8[FWNIQ;7:@%X')!R/8YY7O\
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M'.#STZUGA)6NF>9P?B*=+GI3=F[6\]SU/U%?#O[4F@2Z/\6KNZ8YBU&"*X3
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M+?1=<U'3WSOL[F2W.?5&*\_E5*O<OVL/AS+X8\;?\)!;Q'^S-8^9F50!'<
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MNQ6'R9P""#]T#J?; !]Q>#_%%KXV\*:1X@L4ECL]4M(KR%)E"NJ2(& 8 D9
M/."1Q6]7GG[/'_)!_A__ -@*S_\ 1*UZ'0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZUW%-50J@ 8 Z 4ZD!POQ9^+WAWX,^%GU[Q)<R10;_*@MX5WSW$A&0B+D G
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MO+PU_P!")XW_ /!=%_\ ':^<[+QE<>*OVS] \<>&?"VL:787^JVD<L5Y9%&
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M*O4\'MZG\<+(ZE\&?'MJ I:70;Y5W=-WV=]I_/'Y5\J_\$RU81_$=\?*QTX
M^X%R3_.@#[DHHHH \D^/'[1GAGX!Z7%)JGF:AK-TA-GI-J1YLN,@.Y/W$SQN
M.>^ <&O&M4^,_P"T?=>$+SQG8^!-#TS08U\^+3[E));XP8SYA3S 2 .?NJ?1
M:\3^&&H1_M$?MJ1:MJS?VCI9OKB\@BFX'V>W1C;)MQT!6/((Y^8GJ<_I93V
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M2SC()W''7H*&!Z36;XB8KX?U,@X(M93G_@!K2K!\='_BB/$)/ _LZX_]%-2
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M:"^!&G?'SP2-&O+EM.O[:7[18Z@J;S!)@@@KD;E8'!&>P/45\R>$/V7?VBO
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
